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Abstract
Objective: The research presented here assesses the scientific evi-
dence for the telemedicine intervention in the management of dia-
betes (telediabetes), gestational diabetes, and diabetic retinopathy.
The impetus derives from the confluence of high prevalence of these
diseases, increasing incidence, and rising costs, while telemedicine
promises to ameliorate, if not prevent, type 2 diabetes and its
complications. Materials and Methods: A purposeful review of the
literature identified relevant publications from January 2005 to
December 2013. These were culled to retain only credible research
articles for detailed review and analysis. The search yielded ap-
proximately 17,000 articles with no date constraints. Of these, 770
appeared to be research articles within our time frame. A review of
the abstracts yielded 73 articles that met the criteria for inclusion in
the final analysis. Evidence is organized by research findings re-
garding feasibility/acceptance, intermediate outcomes (e.g., use of
service, and screening compliance), and health outcomes (control of
glycemic level, lipids, body weight, and physical activity.) Results:
Definitions of telediabetes varied from study to study vis-a`-vis dia-
betes subtype, setting, technology, staffing, duration, frequency, and
target population. Outcome measures also varied. Despite these
vagaries, sufficient evidence was obtained from a wide variety of
research studies, consistently pointing to positive effects of tele-
monitoring and telescreening in terms of glycemic control, reduced
body weight, and increased physical exercise. The major contribu-
tions point to telemedicine’s potential for changing behaviors im-
portant to diabetes control and prevention, especially type 2 and
gestational diabetes. Similarly, screening and monitoring for reti-
nopathy can detect symptoms early that may be controlled or treated.
Conclusions: Overall, there is strong and consistent evidence of
improved glycemic control among persons with type 2 and gesta-
tional diabetes as well as effective screening and monitoring of di-
abetic retinopathy.
Key words: diabetes, gestational diabetes, diabetic retinopathy, tel-
ediabetes telemedicine, telemonitoring, telescreening
Introduction
I
n this article, we examine the empirical evidence pertaining to
the effects of the telemedicine intervention on the management
of diabetes (telediabetes), gestational diabetes mellitus (GDM),
and diabetic retinopathy (DR). In an earlier article,1 we focused
on the evidence for the management of three other chronic diseases:
congestive heart failure, stroke, and chronic obstructive pulmonary
disease. Our approach here is similar to the one used in the earlier
article.1 We begin by providing basic information on the nature of
diabetes, including its etiology, epidemiology, and cost. As with other
chronic diseases, diabetes has different manifestations in terms of eti-
ology, severity, age of onset, sequelae, comorbidities, and, most im-
portantly to our purpose, its amenability to control, amelioration, and/
or prevention through telemedicine-supported interventions. This in-
formation establishes a foundation for the inquiry into the nature and
relevance of the telemedicine intervention in this domain. This section
is followed by a description of the literature search and review process,
including the inclusion criteria for the selection of research studies and
the manner in which the resulting empirical evidence is organized. In
the latter instance, analysis of the evidence in telediabetes research is
organized according to diabetes type (type 1 and/or type 2, GDM, and a
common diabetes-related complication, DR). For each of these, the
evidence is organized by research findings regarding (a) feasibility/
acceptance and effectiveness in controlling or ameliorating the course
of diabetes, (b) intermediate outcomes (e.g., use of service, compliance
with screening guidelines), and (c) health outcomes (control of glycemic
level, lipids, body weight, and physical activity).
Diabetes
The term diabetes derives from the Greek diabainein,2 meaning
‘‘siphon,’’ referring to excessive passing of water (urine), and later
from the English adoption of the medieval Latin, ‘‘diabetes.’’ The
disease is also referred to as ‘‘diabetes mellitus’’; the latter term was
added in 1675 by Thomas Willis.3 ‘‘Mellitus’’ derives from the Latin
mel for honey or sweetness (due to the high glucose content of the
urine). Diabetes is a complex group of metabolic diseases—referring
to disorders in the complex set of chemical reactions the body uses to
maintain life, including energy production. As such, it is a clinically
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heterogeneous group of disorders that have hyperglycemia (or high
blood sugar) as a common attribute. Hyperglycemia results from
insufficient insulin hormone secretion by the pancreas, the body’s
inability to respond properly to insulin (insulin resistance), or both.
Insulin is a hormone produced by the pancreas that regulates blood
glucose and allows the body to convert glucose from carbohydrates
to energy. Insulin controls blood sugar levels and keeps themwithin a
normal range. Uncontrolled hyperglycemia results in the body’s cells
being starved for energy because of a lack of insulin. Early compli-
cations of diabetes include damage to the small blood vessels in the
eyes, the kidneys, and the nervous system, which can lead to vision
problems, possibly blindness, kidney disease, neuropathy, and risk of
amputation. A prolonged high blood glucose level damages medium-
size and larger blood vessels that supply the heart and the brain, often
leading to heart disease and stroke. Other long-term complications
include a higher risk for cancer, physical disabilities, depression, and
complications in pregnancy.4
Diabetes has been classified into three types:
. Type 1 (also referred to as insulin-dependent diabetes, juvenile
diabetes, or early-onset diabetes) occurs when the pancreas
cannot make insulin because of damaged or destroyed b cells,
thereby leading to absolute insulin deficiency. Although often
identified in children and adolescents, type 1 diabetes can occur
at any age, accounting for about 5–10% of those with diabetes.
Some forms of type 1 diabetes have no known etiology and
therefore can be referred to as idiopathic diabetes. Insulin
therapy is required for individuals with type 1 diabetes in
combination with diet and exercise.
. Type 2 (also referred to as adult-onset diabetes or non–insulin-
dependent diabetes) occurs when the pancreas does not produce
a sufficient amount of insulin or the cells in the pancreas do not
process insulin properly. It is the most common type of diabetes
(about 90% of cases), and it afflicts people of all ages. Its in-
cidence is associated with age, obesity, and lack of physical
activity. Often, individuals with type 2 diabetes do not need
insulin treatment to survive. In some instances, it may be dif-
ficult to classify patients as having either type 1 or type 2
diabetes. However, the forms of diabetes that have their onset in
young age are different from those that start in adulthood.
. The third type is GDM, which occurs during pregnancy in
women without a history of diabetes. GDM is characterized by
high blood glucose levels, particularly in the third trimester, due
to increased levels of human placental lactogen leading to in-
sulin resistance, which in turn results in high blood glucose
levels. Some women may have had diabetes (type 1 or type 2)
prior to becoming pregnant. The majority of pregnant women
with gestational diabetes can control their glucose with diet and
exercise. If glucose is not controlled, oral medication or insulin
is used. Additional information regarding GDM is included later
in the section on telemonitoring and GDM.
Prediabetes is a condition of high blood glucose levels in which
the b cells are becoming resistant to insulin, but not sufficiently
commensurate to classify the condition as diabetes. This means that
the blood sugar level is higher than normal but not high enough to be
classified as type 2 diabetes. It is characterized by a degree of hy-
perglycemia that can result in pathological and functional changes
before the detection of diabetes. The term prediabetes was introduced
in 1960s, dismissed in 1980 by the World Health Organization,5 and
reactivated in 2003 by the Expert Committee on the Diagnosis and
Classification of Diabetes Mellitus6 to draw attention to this condi-
tion, which is often a precursor to type 2 diabetes. It is estimated that
the vast majority of people with prediabetes (about 90%) do not know
they have it. Without changes in life style, 15–30% of them will
develop type 2 diabetes within 5 years.7
Diabetes Testing
There are three tests for diagnosing diabetes type 1 or type 2: (1)
The most common test is the glycated hemoglobin HbA1c (a subclass
of hemoglobin A) or simply A1c, which measures average blood glu-
cose level over a period of 2–3 months. The test became available in
1978, gained popularity in the 1980s, and was formally adopted by the
World Health Organization in 2011.8 A normal level (no diabetes) is
less than 5.7%. Prediabetes is diagnosed at values between 5.7% and
6.4%. Diabetes is diagnosed at anA1c level of 6.5% ormore. (2) Fasting
plasma glucose (FPG) measures glucose levels after fasting, thereby
improving the reliability of the test. Diabetes is diagnosed at values of
126mg/dL or higher, and prediabetes is diagnosed between 100 and
125mg/dL. (3) The oral glucose tolerance test (OGTT) is a 2-h test that
measures blood glucose before and after a sweet drink. Values of
200mg/dL or higher are indicative of diabetes, and 144–199mg/dL as
prediabetes. Blood glucose can also be tested at random or when there
are severe symptoms, and is interpreted the same way as the OGTT.
Diabetes Epidemiology
In 2014, the overall prevalence rate of diabetes in the U.S. popu-
lation was estimated at 9.3%, or about 29.1 million individuals. Of
these, 21.0 million have been diagnosed, and the remaining 8.1
million were not. That is, about 27.8% of the population who have
diabetes do not know they have the condition.9 In 2012, it was es-
timated that about 86 million people had prediabetes, but only 10%
of them were aware of it. Hence, in the aggregate, nearly one-third of
the U.S. population may have either diabetes or prediabetes but do
not know it. This is important because many of these individuals
would be able to control, if not reverse, the ravages of diabetes
through rigorous monitoring of their glucose levels, focusing on
medication management, as well as weight loss and moderate phys-
ical exercise.
The incidence of diabetes increases with age. For instance, the
estimated rate is 12.3% among people 20 years of age or older and
25.9% of those who are 65 years of age or older. The percentage
difference in the prevalence of diabetes between adult men and
women is rather small (13.6% and 11.2%, respectively).9
The incidence of type 2 diabetes has been increasing during the
last few decades, especially among the young. Historically, type 2
diabetes among persons younger than 20 years of age was extremely
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322 TELEMEDICINE and e-HEALTH MAY 2015
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/08
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
rare, but it is now on the rise, particularly among Native American
and African American populations. This is attributed primarily to
increased numbers of people who are overweight/obese and an in-
creasingly common sedentary life style. During the last decade,
among young people between the ages of 10 and 20 years, the in-
cidence of new cases of type 1 diabetes was 18.6 per 100,000, and that
of type 2 diabetes was 8.5 per 100,000. On the other hand, about 25%
of those over the age of 65 years had type 2 diabetes. On average,
African Americans tend to have a higher level of A1c compared with
whites, suggesting that their glycemic burden may be higher.9
On a global scale, it is estimated that 387 million individuals have
diabetes, representing 8.3% of the world population. This is projected to
increase to 600 million by 2035.10 Whereas diabetes used to be con-
sidered a problem for developed countries, ‘‘77% of the world’s diabetes
populationwill be from low-income andmiddle-income countries, with
over half from Southeast Asia and the Western Pacific regions.’’10
Diabetes is the seventh leading cause of death and a major cause of
disability in the United States. However, this ranking may be un-
derestimated because diabetes is a major cause of heart disease and
stroke. It is also the leading cause of kidney failure, lower limb am-
putations, and new cases of blindness among adults.11 According to
the Centers for Disease Control and Prevention, ‘‘the risk for death
among people with diabetes is about twice that of people of similar
age but without diabetes.’’4
As mentioned above, the major risk factors in type 2 diabetes are
overweight/obesity and sedentary life style. It is important that sig-
nificant weight loss and a healthy life style can reduce the risk of type
2 diabetes by nearly 50%.4 Indeed, there is a potential for ‘‘reversal’’
of the disease in some cases. Also, the risk of diabetes among persons
with prediabetes can be decreased by nearly 60% if they lose a sig-
nificant amount of body weight (about 7%) and increase moderate
physical activity to minimum of 150min/week.4,12 Among pregnant
women with GDM, the risk for developing diabetes after delivery is
35–60% higher compared with their counterparts.4
Diabetes Cost
A study commissioned by the American Diabetes Association,
entitled ’’Economic Costs of Diabetes in the U.S. in 2012,’’13 estimated
the total cost of diagnosed diabetes at $245 billion. This was up from
$174 billion in 2007, representing a 41% increase in 5 years, at an
annual rate of increase of 8.2% or $14 billion. Of this amount, $176
billion were spent on direct medical care, and $69 billion were at-
tributed to productivity loss. The largest components of direct
medical expenditures were hospitalization (43%), medications (18%),
agents and supplies (12%), physician office visits (9%), and nursing/
residential facility stays (8%). During the same 5-year period (2007–
2012), the average annual medical expenditures for a person with
diabetes were estimated at about $13,700. Nearly two-thirds, or
62.4%, of the direct medical cost of diabetes is borne by government
programs (including Medicare, Medicaid, and the military). However,
these estimates do not include the cost of undiagnosed diabetes, the
burden of pain and suffering, or the care provided by unpaid care-
givers. For example, it is estimated that families having a child with
diabetes devote about 10% of their family income for diabetic care.14
Overall, medical expenses for people with diabetes are more than
twice (2.3 times) that for people without diabetes.4
Telediabetes
The lives of the vast majority of people with diabetes—including
those diagnosed with the disease, those at the threshold of developing
diabetes, and those who have diabetes and do not know it—are ad-
versely affected by this pernicious disease. Yet, this is one chronic
disease (especially type 2 diabetes) that can be controlled, if not pre-
vented, by appropriate behavioral changes on the part of thosewho are
affected or at risk. Type 2 diabetes is progressive, often requiring
treatment with one or more non-insulin therapies. Insulin therapymay
be needed in order to achieve optimal glycemic control. Type 1 dia-
betes requires frequent monitoring and medication titration. Regard-
less of type, in order for patients with diabetes to take appropriate
measures for managing their condition, they need early diagnosis,
regular glucose monitoring, and individualized treatment plans that
address their emerging needs, as well as ongoing clinical support and
guidance that prompts and assists them to take appropriate preventive/
maintenance measures to optimize their health and well-being.
In general terms, telediabetes serves two related goals: (1) control
of blood glucose through a healthy life style, including proper diet
and weight reduction among overweight or obese individuals, as well
as increased regular physical exercise, and (2) medication manage-
ment, including insulin titration. Telediabetes provides the tools for
routine and ongoing monitoring of blood glucose levels, patient-
specific management plans, and educational materials, instruction,
and reinforcement/support strategies for the adoption of a healthy
life, as indicated by an individual’s relative risk. Once the system is in
place, its components serve as an effective communication link be-
tween patients and a professional support team that responds
promptly to patients’ needs and inquiries.
Telediabetes shares some of the same attributes of telemonitoring
for other chronic conditions, such as congestive heart failure, stroke,
and chronic obstructive pulmonary disease. In fact, all these inter-
ventions constitute essential elements of comprehensive chronic
disease management wherein patients are expected to assume sub-
stantial responsibility for managing their own health and healthcare
while being monitored and guided actively by clinical providers
through telephony, videoconferencing, or other electronic devices on
a routine basis. The typical telediabetes system provides patients with
electronic tools to measure blood glucose levels, to report this in-
formation to a care coordination clinic, staffed by nurses and/or
dietitians, and to receive guidance on proper steps to control their
glucose levels, thus enhancing their health and well-being. The
electronic system collects, stores, and processes the data provided by
patients, establishes trends in the progression of the disease for each
patient, and gathers other case-specific information over time. It has
built-in and protocol-driven trigger alerts for response or action
when certain clinical markers are exceeded. In brief, the ultimate aim
of chronic disease management systems is to assure that patients
receive the ‘‘appropriate care at the appropriate time and place in the
TELEMEDICINE FOR DIABETES MANAGEMENT
ª MA R Y A N N L I E B E R T , I N C .  VOL. 21 NO. 5  MAY 2015 TELEMEDICINE and e-HEALTH 323
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/08
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
most appropriate manner.’’15 Telediabetes brings this goal closer to
fruition.
In general, telediabetes incorporates essential elements of patient-
centered care, as it focuses on the patients’ specific health needs and
engages them in their own care. The corollary concept of the medical
home is intended to coordinate the services and referrals across a
continuum of care for the patient.16,17 These two concepts are often
combined in the patient-centered medical home to describe an in-
novative model18 of care coordination and delivery that serves the full
spectrum of healthcare needs of a patient. Telemonitoring also incor-
porates the concept of shared decision-making, which has been ad-
vocated since the 1970s as the ideal model for decision-making on the
part of patients when confrontedwith a consequential range of choices
in their care.19 Shared decision-making embodies the principle of in-
formed consent, which stipulates that the patient has to agree to any
proposed medical treatment prior to its initiation. It reinforces the
patient’s right to informed choice and the role of the provider as an
agent of the patient. Accordingly, the patient would be given explicit
information regarding treatment options and their potential conse-
quences in terms of benefits and risks. The same principle is extended
to other critical decisions confronting patients such as going to the
emergency department or other options. Indeed, the informed consent
requirement is now commonplace in healthcare delivery.
Telemonitoring systems facilitate the patient-centered medical
home by linking patients and providers through a variety of tele-
communications options and systems. These systems may be auto-
mated or not, fixed or mobile, possibly wearable or implantable.
Some require the patient to collect and transmit the data to a des-
ignated clinical center, where they are stored, processed, and sub-
sequently used to help the patient. In addition, some systems contain
educational materials that are tailored to the individual patient needs,
typically focusing on glycemic control, weight control, physical
activity, and smoking cessation. The providers have ready access not
only to the monitored information on glucose levels, lipid levels, and
other clinically relevant parameters, but also to the patients’ medical
histories where electronic personal health records are available. The
system contains interactive tools to help patients with critical deci-
sions, such as the interpretation of symptoms and conditions as well
as the options regarding treatment modalities.
There is near consensus in the field that type 2 diabetes can be
controlled (if not prevented), that treatment and guidance protocols can
and should be customized to fit the needs of individual patients, and
that patients with diabetes should be monitored on a regular basis.20
The Review Process
The analysis of the empirical evidence in telediabetes research
entailed four steps: (1) an initial literature search for all publications
using the key terms ‘‘telemedicine,’’ ‘‘telehealth,’’ ‘‘telemonitoring,’’
and ‘‘diabetes’’ to identify all relevant publications from January
2005 to December 2013; (2) a culling of references to select research
articles only, eliminating editorials, case reports, and project de-
scriptions; (3) a review of abstracts of research articles to determine
eligibility for inclusion in the final list, using the two inclusion
criteria, namely (a) a randomized clinical trial (RCT) or another robust
research design and (b) a sample size of 150 or more cases to assure
statistical power; and (4) a detailed review of complete manuscripts
of publications in the final list of eligible articles. A few exceptions
were made in the selection of the final list for analysis where sample
size was smaller than 150, the RCT design was not used, or both. The
decision to include these articles was based on their contribution to
our understanding of innovative methods in diabetes monitoring
such as the use of an interactive diary, or when an RCT design was not
the method of choice for the particular research objectives under
investigation, such as the estimation of incidence or prevalence rates,
the measurement of other population-based parameters, or feasibility
assessment of certain monitoring modalities or interventions. How-
ever, studies that did not investigate the effects of telediabetes or
produced empirical evidence of the merit of telediabetes were not
included in the discussion and tabular presentation of the empirical
evidence. The rationale for the time limit to one preceding decade has
to do with the rapid pace of technological development, whereby
older technologies have become obsolete in terms of functionality,
ease of use, cost, and ubiquity.
Step 1 in the review of the past 10 years yielded approximately
17,000 articles. Of these, 770 appeared to be research articles. A
review of the abstracts of these 770 yielded 73 articles that met the
inclusion criteria for this analysis. Of these, 21 were focused on tele-
diabetes, plus 9 studies conducted at the Veteran Health Adminis-
tration (VHA) and 16 reports from one project, the Informatics for
Diabetes Education and Telemedicine (IDEATel). An additional set of
four studies was focused on GDM, and 23 focused on DR.
One final note regarding the complexity of the evidence in tele-
diabetes research is in order. The empirical findings reported here
derive from a rich mixture of research studies that were conducted in
different countries and settings, with different patient populations,
using different configurations of technologies and human resources,
and also using different research protocols. More specifically, the
studies differed in terms of (a) the selection of patient populations by
diabetes type (type 1 diabetes, type 2 diabetes, or both; GDM; and
patients with DR), (b) the technological configuration of the inter-
vention (telephone or video, automated or manual, machine captured
or patient reported, with or without trend displays, provider-only
accessed or shared with the patient), (c) provider mix and healthcare
setting, and (d) the duration and intensity of the intervention. Hence,
it is important to interpret the findings from this research in relation
to the context, the particular research configuration, and the specific
input variables that were used. Moreover, there were variations in the
specific effects measured, including intermediate outcomes, such as
use of service and compliance with screening, as well as health
outcomes, including glycemic control, desirable lipid levels, weight
and/or body mass control, and health knowledge pertaining to dia-
betes and its management.
In view of the variety of diabetes types, methodological designs,
and outcome measures, we decided to organize the evidence of tel-
ediabetes initially by categories of the disease: (1) diabetes type 1
and/or type 2, (2) GDM, and (3) DR. Subsequently, we report on the
BASHSHUR ET AL.
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empirical evidence of telediabetes for each of these disease categories
in terms of three sets of findings: (a) feasibility and/or acceptance, (b)
intermediate outcomes (e.g., adherence to screening or other pre-
scribed regimen, use of service), and (c) health outcomes. We limited
the analysis of the empirical evidence to categories (b) and (c). In
addition, where available, we included studies of cost-effectiveness.
We encountered one prolific project, called IDEATel, that pro-
duced 18 publications. We decided to review all the articles published
from this project as a separate set, as will be seen later in this review.
The VHA presented another context where multiple research articles
were published using a similar context. Most of these are combined as
a set in the discussion.
Telediabetes for Type 1 and/or Type 2 Diabetes
A recent ‘‘review of reviews’’ of the evidence from studies in tele-
diabetes was published in 2013.21 It was designed to assess the relative
effectiveness of four quality improvement strategies—namely, patient
education and support, telemedicine, provider role changes, and or-
ganizational changes. The selection of only ‘‘high-quality systematic
reviews’’ resulted in 21 studies on patient education and support, 10 on
telemedicine, 7 on provider role changes, and 4 on organizational
changes. However, the authors noted that several studies investigated
combinations of strategies, and they classified eight as such. In any
case, the authors used a ‘‘votingmethod’’ to determine the effectiveness
of each of these strategies on glycemic control, retinopathy, and vas-
cular risk factors such as blood pressure, low-density lipoprotein (LDL)
cholesterol, and/or diabetic foot outcomes. Among the 10 reviews that
focused on telemedicine in this review, the number of studies included
in each individual review varied from five to eight, and all were
conducted between 1976 and 2011. However, based on the evidence
from ‘‘credible reviews’’ dealing with three of the four strategies, the
authors concluded ‘‘that patient education and support, provider role
changes, and telemedicine are associated with improvements in gly-
cemic control and vascular risk factor control in patients.’’21 Appar-
ently, there was no such evidence for organizational changes.
The authors noted considerable overlap among these three strat-
egies, as many of the interventions/strategies did not fit into a single
category. This raises questions regarding the validity of their classifi-
cation scheme because the input variables did not fit into mutually
exclusive categories. Hence, there is no way to ascertain the relative
effectiveness of a specific intervention or strategy or, more critically
for our purposes, how to interpret the telemedicine effect when it is
stripped of some of its essential components, such as patient education,
provider participation, and organizational realignment.
Feasibility and Acceptance of Telediabetes
As mentioned earlier, this initial section of the analysis focuses on
studies that investigated the feasibility and/or acceptance of the
telemedicine intervention in type 1 and/or type 2 diabetes (tele-
diabetes). The findings are presented in historical order, covering
those published from 2005 to 2013. As mentioned earlier, many of
these of these studies did not meet the requisite sample size for in-
clusion in the analysis of empirical findings. Hence, the studies that
were solely concerned with feasibility and/or acceptance of tele-
diabetes are discussed here, but they are not included in the analysis
of the empirical evidence of the effects of telediabetes.
We identified 11 feasibility-related studies that met the selection
criteria for this set. These were conducted in six countries: (United
States [n = 4], Australia [n = 2], Germany [n = 2], Italy [n = 1], Canada
[n = 1], and the United Kingdom [n = 1). Sixty percent of these studies
were based on an RCT design. Sample size varied from 120 to 538.
FromAustralia (2006), an RCT (n = 139 pediatric patients with type
1 diabetes) investigated the effectiveness/feasibility of making
scheduled telephone calls from a ‘‘pediatric diabetes educator’’ on a
bimonthly basis.22 The mean age of the patients was about 12 years.
Hence, it can be assumed that parents/guardians provided much of
this information. The educator inquired about glucose level, hospital
admissions, diabetes knowledge, compliance, and psychological
well-being. After 7 months of observation, there were no significant
differences between the experimental and control groups on the
measured variables, but the patients or their caregivers reported that
the telephone calls were helpful.
A Canadian study (RCT, n = 193) investigated the feasibility of an
automated telephone reminder system, using interactive voice rec-
ognition, and its effects on medication and appointment adherence
among adult patients (18 years of age or older) who had access to a
telephone.23 In total, 253 patients were enrolled from 47 physician
practices, and they were randomly assigned to the intervention or
usual care group. The enrollment process was facilitated by the use of
electronic medical records. In total, 193 patients were successfully
registered in the system, and they were subsequently observed over a
period of 7.5 months. ‘‘Success’’ was defined as the actual receipt/
completion of automated telephone reminders without the inter-
vention of a human operator. The study revealed that the average
percentage of successful reminders declined as the number of mes-
sages increased. Overall, 81% of patients in the intervention group
received/completed at least three successful reminders, and 50%
received/completed at least five reminders. Overall, the main finding
from this study documented the feasibility of the automated tele-
phone system as a substitute for a human operator.
Another telephone-based self-management telediabetes program
evaluated the incidence of adverse events among ambulatory dia-
betes patients in 2008 (n = 111).24 This U.S. study was unique in terms
of focusing on safety issues and adverse event characteristics, in-
cluding detection triggers, preventability, potential for amelioration,
and primary care provider awareness of such events. The findings
suggest that telephone surveillance ‘‘facilitated self-management
support program.to detect adverse events and potential adverse
events.’’24 Often, without this system, providers were not aware of
such events. Thus, the authors concluded that the system ‘‘can im-
prove patient safety for chronic disease patients.’’24
In 2009, a British RCT (n = 137) evaluated the effects of a mobile
phone telediabetes system on glycemic control among patients with
complicated diabetes.25 Patients were asked to measure their blood
glucose level with a sensor on a regular basis. The values were sub-
sequently transmitted to a mobile phone via a wireless Web-based
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application. The usual providers received the readings on mobile
phones and responded with appropriate guidance via a mobile
phone. After a follow-up of 9 months, patients in the intervention
group had a lower A1c level compared with the control group: 7.7%
versus 8.4%, respectively. However, this study is not included in the
tabular material because of the small sample size (n = 137). The
findings supported the utility of mobile devices in the management
of diabetes.
Three relevant studies were conducted in 2011. The first was a
composite, or multipart, study in Germany. The first component of
this study was a survey of physicians who provided care for 538
patients with type 1 or type 2 diabetes (only 4.1% of the sample had
type 1) for more than 1 year in the Karlsburg Diabetes Management
System. The survey focused on the acceptance of the system by the
physicians who provided care for these patients.26 The second com-
ponent was a retrospective analysis of data for a subset of 289 pa-
tients who completed two glucose monitoring sessions during 1 year.
The program was open for patients with diabetes who were 18 years
of age or older and also diagnosed with cardiovascular disease (in-
cluding angina, history of myocardial infarct, or heart failure [New
York Heart Association class 3 or 4]). Nearly three-quarters (74%) of
the participating physicians (n = 276) accepted (or were satisfied
with) the system. Among the 289 patients who completed two sets of
routine glucose measurements, 214 used the telemedicine system,
and 75 did not. The authors concluded that the monitoring system ‘‘in
combination with telemedicine has high potential to improve the
outcome of routine outpatient diabetes care.’’26
From the United States (2011), an observational study of 117 pa-
tients with diabetes type 1 or type 2 reported on the feasibility of
incorporating a telediabetes system into an existing telephonic dia-
betes management program.27 The primary outcome measure was
change in glucose level, and the secondary outcomes were patient
knowledge and engagement. The unique feature of this study was the
use of clinical pharmacists as providers. A survey of patient satis-
faction with the program reported high levels of satisfaction but no
improvement in knowledge about diabetes management. The clinical
findings confirmed the feasibility of this intervention as indicated by
a decrease in A1c of 1.3% during a period of 4 months. Moreover, the
users were satisfied with the service.
Another feasibility study, also from the United States, was con-
ducted over a 3-year period (n = 206 in year 1, but the number de-
clined to 135 in year 2). The findings were reported in 2011.28 This
was a nonrandomized, pre–post study of patients with type 2 diabetes
who also had at least one uncontrolled vascular risk factor. It com-
pared participants from two rural clinics in Montana who were en-
rolled in a telediabetes program versus those receiving usual care.
The project was aimed at determining (a) the feasibility of a team
approach in telediabetes and (b) its effects on clinical outcomes.
Feasibility was assessed in terms of patient acceptance, patient self-
management behaviors, and diabetes knowledge. Clinical outcomes
were measured by control of diabetes risk factors. The authors con-
cluded that telediabetes ‘‘proved to be an effective mode for the
provision of diabetes care to rural patients,’’ by achieving results
comparable to in-person care while ‘‘addressing the unique chal-
lenges faced by patients living in rural communities.’’28
An Australian RCT (2012) (n = 120 patients with type 2 diabetes)
investigated the feasibility and accessibility of an interactive voice
recognition telephone system among children and adolescents.29
After 6 months of observation, patients in the telediabetes group had
a significantly greater decline in A1c, from 8.7% to 7.9%, compared
with 8.9% to 8.7% in the control group.
In the same year, a German observational study was conducted
among 124 children and adolescents who were overweight or ob-
ese.30 The purpose of that study was to determine the acceptance and
effectiveness of a sophisticated mobile motion sensor device and a
digital camera integrated into a mobile phone. Outcome measures
included physical activity and eating habits. The subjects readily
accepted the movement detection system. More important is the
finding that the use of the system resulted in significant weight re-
duction in this young population.
Two feasibility studies were published in 2013. The first was an
RCT (n = 100) conducted in the United States. It used telephone and
Internet links to connect providers with diabetes patients, and it was
aimed at determining the congruence between routine clinical tele-
diabetes assessments and in-person care assessments.31 Patients were
randomly assigned to experimental or control groups in equal pro-
portions. After 12 months of observation, no differences were ob-
served between the two groups in terms of glycemic control, lipids, or
body mass index. In terms of feasibility, the authors concluded that
the use of ‘‘telemedicine-based treatment protocols in diabetes pa-
tients is feasible and efficient ..’’31
The second study published in 2013 was also an RCT (n = 127, all
with type 1 diabetes), conducted in Italy.32 In this study, patients used
an automated carbohydrate/bolus calculator (referred to as Diabetes
Interactive Diary [DID]) to calibrate the individual’s appropriate in-
sulin dose for each meal. The patients were instructed by physicians
and/or dietitians on how to record the results of glucose profiles,
daily insulin doses, and hypoglycemic episodes. Additionally, par-
ticipants were required to complete a quality of life questionnaire at
the start of the project and 6 months after randomization. The results
demonstrated the feasibility and comparability of using the DID in
terms of the outcome equivalence to in-person traditional carbohy-
drate counting insofar as A1c levels were concerned. The risk of
moderate/severe hypoglycemia was reduced while quality of life
improved. Three years earlier (2010), the same senior author and a
different set of co-authors published results on the effectiveness of an
Interactive Diary for Diet Management (DAI [Un Diario Alimentare
Interattivo]).33 That was a prospective observational study of 140
participants who participated in the DAI and were trained and
monitored by dietitians to determine its impact on body weight
management and nutritional status. The DAI software was designed
to support the patients in their daily management of food intake, and
it was installed on the patients’ mobile phones. The study docu-
mented the feasibility of this technology in supporting people who
need to lose body weight and also to promote the healthy properties
of the Mediterranean diet and consumption of local produce.
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Still earlier, in 2010, a different kind of study was published in
Italy, using the same DID.34 This was an RCT with a sample of only
130 patients with type 1 diabetes. The sample was somewhat
smaller than the required size, but we include this study here be-
cause it used a novel approach for metabolic and weight control—
namely, the DID. The purpose of the study was to determine
whether the use of this tool would improve glycemic control in a
shorter time and with greater ease compared with the standard
educational approach. The DID had several functions, including a
carbohydrate/insulin bolus calculator, an information technology
device, and a text messaging system between provider and patient.
It contained a complex educational tool to help patients with di-
abetes follow a flexible insulin therapy and dietary carbohydrate
intake: ‘‘Bolus insulin is adjusted to match the dietary carbohy-
drate at each meal.’’34 The software was installed on patients’
mobile phones to record blood glucose levels and insulin injection
in real time and to receive advice on daily carbohydrate and calorie
intake (facilitated by visual images). The results of the study
demonstrated the safety and effectiveness of the DID, as well as its
time efficiency and ease of use.
Telediabetes and Intermediate Outcomes:
Adherence and Use of Service
Data on intermediate outcomes of telediabetes are shown in
Table 1.
To start, a large-scale observational study, conducted in Tennessee
(n = 36,327), was published in 2006; it investigated the effectiveness
of a nurse-led telephonic management program on adherence to
prescribed glycemic testing.35 Frequency of calls was determined on
the basis of disease severity. In addition to telephone calls, the pro-
gram provided quarterly newsletters, reminder mailings, and disease-
specific educational materials. Participants in the program had
moderate to severe risks for diabetes complications. Data on adher-
ence to testing were gathered at 6 months before and 6 months after
the start of the program. The findings revealed a significant increase
of 29% in A1c testing among the participants, potentially reducing
the risk of exacerbation.
Three studies meeting the inclusion criteria investigated the effects
of telediabetes on use of service. All three were conducted in the
United States and published in 2011 and 2012.
A 4-year case-control study assessed the effects of the VHA Care
Coordination Home-Telehealth Program on use of service among
veterans diagnosed with diabetes (type unspecified).36 An interven-
tion sample of 387 patients was selected from one of four clinics in a
single VHA region. This group was matched by age and gender to
create a control group of 387 at the date of enrollment. A ‘‘propensity
score’’ was used in matching the two groups in order to reduce se-
lection bias. However, this process did not result in full equivalence
between the intervention and control groups. At baseline, the former
group had a significantly higher comorbidity score, signifying a
sicker population. Also at baseline, the number of inpatient days was
similar in the two groups, but the number of outpatient visits was
greater in the intervention group. At the conclusion of 48 months,
‘‘there was a general pattern of reduced inpatient and outpatient use
by the intervention group compared to the control group ..’’36
Another case-control study investigated the effects of post-
discharge monitoring through the use of interactive voice response
on 30-day hospital re-admission rates in 2012.37 A sample of 875
patients enrolled in a case management Medicare Advantage
program using the sophisticated telephone system was compared
with a matched group of 2,420 controls who had case management
only. Matching was at the rate of 1 (case):3 (controls). The major
result of this study indicated a 44% reduction in rehospitalization
among patients who received a combination of telemonitoring and
case management compared with patients receiving case man-
agement only.
An RCT (n = 762), also U.S.-based, investigated the effects of a
nurse-monitored algorithm-driven telephone care management
program on several dependent variables, including lipid manage-
ment, blood pressure, glycemic control, primary and subspecialty
care follow-up, cost to the system, and hospital admissions.38 The
subjects were adults with diabetes (type unspecified) receiving care
at a Federally Qualified Community Health Center that served a
primarily indigent Latino population. Patients in the intervention
Table 1. Telediabetes Intermediate Outcomes
INTERMEDIATE OUTCOMES
REFERENCE (YEAR) COUNTRY
RESEARCH
DESIGN
SAMPLE
SIZE ADHERENCE USE OF SERVICE COMMENTS
Orr et al.35 (2006) United States Observational 36,327 [ NM 29% increase in A1c testing
Jia et al.36 (2011) United States Case-control 387 NM Y Inpatient and outpatient use of serviceY
Graham et al.37 (2012) United States Case-control 875 NM Y 44% reduction in rehospitalization
Fischer et al.38 (2012) United States RCT 762 NM Y Average per patient costY$2,816; LDLY6.5%,
hospital admission rateY5.55%; A1c and
BP no difference
A downward arrow indicates decreased.
A1c, glycated hemoglobin A1c; BP, blood pressure; LDL, low-density lipoprotein; NM, not measured; RCT, randomized clinical trial.
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group received calls from nurses to help them initiate and titrate
lipid-lowering medications using standard guidelines and to en-
courage them to adopt healthy lifestyle behaviors. The usual care
group received standard diabetes management by primary care
providers, which consisted of regular clinic visits. After 20 months,
the intervention group had substantially lower hospital admission
rates relative to the control group (19.6% and 25.2%, respectively).
Furthermore, the average cost per patient for the health system was
$6,217 for the intervention group versus $9,033 for the control
group. As well, the intervention resulted in improved lipid control
(from 52.0% to 58.5%) in the intervention group versus from 55.6%
to 46.7% in the control group, but it had no effect on glycemic level
or blood pressure.
Telediabetes and Health Outcomes
The vast majority of studies that investigated the effects of tele-
diabetes on health outcomes focused on glycemic control as the
primary metric, often in combination with other diabetes risk factors,
such as body weight, diet, lipids, blood pressure, and insulin titration.
These data are summarized in Table 2. Few studies measured
Table 2. Telediabetes Outcomes
OUTCOMESREFERENCE
(YEAR) COUNTRY
RESEARCH
DESIGN
SAMPLE
SIZE A1C BP LDL WEIGHT/BMI COMMENTS
Harno et al.39 (2006) Finland RCT 175 Y Y Y NM Fewer physician visits
Rodrı´guez-Idı´goras
et al.40 (2009)
Spain RCT (parallel
groups)
328 Y Y Y Y Control group showed improvement but less
Berg et al.41 (2009) United States Case-control 980 *Y NM O NM ROI 3.8:1; inpatient bed daysY48%; costY
Anderson et al.42
(2010)
United States RCT 295 Y O O O No difference in A1c at 6 and 12 months;
lifestyle changes need longer duration;
A1cYfor those with depression
Davis et al.43 (2010) United States RCT 165 Y O Y O Self-reported data
Jordan et al.44 (2011) United Kingdom Case-control 473 Y Y NM Y BMI Y 0.7 units; BP Y; A1c Y 0.3%; small Y in LDL
Musacchio et al.45
(2011)
Italy Observational 1,004 Y *Y Y O Metabolic and cardiovascular risk[
(face-to-face visitsY)
van Bastelaar
et al.46 (2011)
The Netherlands RCT 255 O NM NM NM Duration= 1 month; depressionY; Web-based
cognitive therapy helpful
Charpentier et al.47
(2011)
France RCT 180 Y NM NM NM Less patient travel
Franc et al.48 (2014) France RCT 180 Y NM NM NM Portion and carbohydrate counting[
Stamp et al.49 (2012) France Descriptive
observational
330 Y O NM NM A1c Y 1.8%
Tang et al.50 (2013) United States RCT 415 Y at 6
months
O Y at 12
months
O Intervention group better at 6 months but
even at 12 months; medication management[
Ellis et al.51 (2012) United States RCT 146 Y NM NM NM Adolescent adherence[
Kesavadev et al.52
(2012)
India Retrospective
record review
1,000 Y Y Y Y Used no controls
Chen et al.53 (2013) Taiwan Longitudinal
case-control
162 Y NM NM NM Invervention group [blood glucose monitoring;
[physical activity, diet, medication compliance,
coping, problem solving; A1c stabilized at
18 months
Brown-Guion
et al.54 (2013)
United States Survey 1,797 NM NM NM NM Urban/rural ethnicity differences in diabetes
education
Lee et al.55 (2013) Korea Tech assessment 1,568 NM NM NM NM Voice diagnostic tools for predicting BMI
A downward arrow indicates down or decreased; an upward arrow indicates up or increased.
A1c, glycated hemoglobin A1c; BMI, body mass index; CR, cluster randomization; LDL, low-density lipoprotein; NM, not measured; O, no difference; QE, quasi-
experimental; ROI, return on investment.
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intermediate health outcomes, such as frequency of reporting blood
glucose levels, emotional distress, and knowledge of diabetes risk
factors. One study48 used the term ‘‘informed meals’’ as a measure of
appropriate diet for persons with diabetes.
Published in 2006, an RCT (n = 175) conducted in Finland involved
patients with type 1 or type 2 diabetes who were served by primary
care clinics and university hospital outpatient departments.39 The
patients were randomly assigned to the intervention (n = 101) or
control (n = 74) group. The intervention group was supplied with an
electronic disease management system and a home care link. This
allowed both patients and providers to send and receive short mes-
sage service (text messages) on either mobile phones or the Internet.
Patients in the intervention group downloaded their measurements
directly, and the data were available to the care team as well as the
patients themselves. In addition, providers had access to the patients’
diaries, which contained daily entries. Those in the control groupmade
regular visits to their usual providers about once every 3 months. After
12 months in the program, both groups experienced a decline in their
A1c lelvel, but the decline in the intervention group was greater (and
statistically significant) than that in the control group (from 7.8% to
7.3% versus from 8.2% to 7.8%, respectively). In addition, only pa-
tients in the intervention group experienced significant declines in
cardiovascular risk factors such as blood pressure and lipids. The other
benefit was a reduction in demand for care, that is, ‘‘fewer visits [were
made] by study patients to doctors and nurses.’’39
Four research articles that met the inclusion criteria were pub-
lished in 2009.
A study in Spain used ‘‘a controlled randomized two-parallel
group trial’’ to ascertain the effects of a telediabetes program on
glycemic control, lipids, body weight, and blood pressure.40 A two-
step selection method was used. The first step identified a sampling
frame consisting of 35 physicians and 24 nurses from the Province of
Malaga who agreed to participate in the study. The second step
consisted of selecting 8–10 subjects from each medical practice.
Subsequently, these patients were randomly assigned to the inter-
vention (n = 161) or control group (n = 167). All patients were 30
years of age or older and had type 2 diabetes. At the beginning of the
study, all study patients received a glucose meter. Patients in the
intervention group and their physicians also received mobile phones,
which were linked to a call center. The patients used the mobile
phones to report their glucose measurements. An alarmwas triggered
when prespecified values were exceeded, and these alarms were ad-
dressed promptly by a physician or a nurse providing appropriate
instructions. Physicians had access to all information submitted by
patients. At 6months, both intervention and control groups experienced
significant reductions in A1c. However, at 12 months, the decrease in
A1c was statistically significant in the intervention group but not in the
control group (from 7.62% to 7.40% versus from 7.44% to 7.36%, re-
spectively). Similar trends were observed in lipids and blood pressure,
but these improvements were sustained in the intervention group only.
A case-control study (n = 980) in Puerto Rico investigated the ef-
fects of a telediabetes program on use of service, selected clinical
outcomes, and financial impact.41 A sample of 490 (age range, 18–64
years) Medicaid patients with diabetes was matched with 490 con-
trols. Composite ‘‘propensity scores’’ were used for matching the two
groups, which included demographic characteristics, comorbidities,
use of service, medications, diagnostic tests, immunization history,
and medical and pharmacy costs. The use of these scores was in-
tended to maximize the similarity between the intervention and
control groups. The intervention group received a customized self-
management disease program that contained risk stratification (i.e.,
levels of risk), organized nurse-led educational sessions, 24-h access
to nurse counseling, and organized information sources for advice on
symptoms, as needed. In addition, patients in this group received
individualized assessment letters and reminders for medication
compliance and vaccinations. The control group received usual care
without the disease management program. Contacts were made pri-
marily by telephone. At 12 months, the intervention group experi-
enced significant improvements, including ‘‘48% reduction in
inpatient bed days, and a 23% increase in ACE [angiotensin-
converting enzyme] inhibitor use, resulting in a return on in-
vestment of 3.8:1.’’41 Overall, ‘‘the intervention group had costs of
$122,306, and generated gross savings of $463,814’’41 or net sav-
ings of $341,508. The intervention resulted ‘‘in a 24.2% reduction
in the cost of care.’’41
Two more studies were published in 2009 by authors at the VHA.
These will be discussed later under a separate section dealing with
VHA studies.
The first of four RCTs published in 2010 (n = 295, all type 2 dia-
betes) focused on a medically underserved population (80% were
below the poverty level). Most were Hispanic or African American,
nearly half spoke a language other than English at home, and all were
served by a Federally Qualified Community Health Center.42 In total,
1,754 patients were eligible for inclusion in the study. Of these, 1,704
were contacted, 333 were interviewed, and 295 consented to par-
ticipate and met the criteria for inclusion in the study. This final
group was randomly assigned to the intervention (n = 146) or control
(n = 149) group. Only 94 of the intervention group completed the
study, whereas 117 did so in the control group. The intervention
group received telephone calls in addition to usual care, which were
intended to promote a healthy life style. The control group received
usual care only. Assessment of A1c at 6 and 12 months showed no
difference between the intervention and control groups. The only
exception was an improvement of A1c value among patients with an
established diagnosis of depression, but the difference was not sta-
tistically significant. However, the control group had a significantly
higher A1c than the intervention group at baseline, thereby sug-
gesting selectivity bias in the choice of the two groups. The authors
explained that 1-year duration ‘‘was insufficient to realize benefits
from an intervention geared at promoting life style changes. Such
changes may take time to enact and show benefits.’’42
A somewhat similar study of telediabetes (RCT; n = 165) was
conducted in a medically underserved community in South Car-
olina.43 Here again, the patients had diabetes (predominantly type 2)
and were using a Federally Qualified Health Center. Most were Af-
rican American (75%), female (73%), and obese (average of 101 and
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96 kg, respectively, for the two groups). Initially, telephone contacts
were attempted with a large pool of 1,984 patients who were iden-
tified from billing records as tentatively eligible for the study. Of
those meeting eligibility criteria and also consenting to participate in
the study, 165 completed two in-person screening visits and con-
sented to participate. These were randomly assigned to the tele-
medicine intervention or in-person group. The intervention group
received structured and comprehensive educational materials deliv-
ered by videoconferencing in group sessions. The materials were
based on a theoretical health belief and health behavior model. Each
patient in the usual care group received one 20-min diabetes edu-
cation session from a licensed practical nurse during the randomi-
zation process. High retention rates of 90.9% and 82.4% were
observed among both groups at 6 and 12 months, respectively. Re-
sults showed significant reductions in A1c and LDL in the interven-
tion group only, but no statistically significant differences were
observed in body weight between the two groups.
In 2011, four studies from four countries (United Kingdom, Italy,
The Netherlands, and France) met the inclusion criteria for analysis
and focused on health outcomes.
The first British case-control study examined the effects of a
telephone-based, nurse-delivered motivational coaching and sup-
port system for self-management and life style changes among
patients with poorly controlled diabetes. The study used a unique
case-control methodology.44 A sample of 473 patients 18 years of
age or older with poorly controlled diabetes was enrolled in a
telephone care management service. The patients were matched
with a comparable disease status group pool of 21,052 (selected at
the rate of almost 1:50) as a control cohort. The choice of such a
large control group would ensure the control sample’s representa-
tiveness of the population from which it was drawn. However, the
true test of an effective case-control design is the comparability of
the two groups with each other. A very large sample of controls
means that this group will have a negligible sampling error in re-
lation to its population. Eligibility for inclusion in this study was
based on age (18 years or more) and one or more of the following
conditions: noncompliance with medication, hypertension, dia-
betic complications, and an assessment by a clinician of the like-
lihood to benefit from the service. This latter criterion was not
explicitly defined.
Each consenting adult was assigned a nurse care manager who had
completed a 6-week training program in all aspects of diabetes care
management and education. Once enrollment was implemented, the
nurses initiated individualized advice on the telephone in a sup-
portive fashion and encouraged the patients to set their own goals.
The program was ongoing as of the date of the publication of the
article, but the data for the publication were based on 90 days or more
of observation. After adjusting for confounding factors, ‘‘the inter-
vention showed significant reductions in A1c, average of 0.3% (0.1
versus 0.4); 3.5mmHg in systolic blood pressure and 1.6mmHg in
diastolic blood pressure; and 0.7 unit reductions in BMI [body mass
index], over a follow-up period averaging around 10 months.’’44 It is
important that a stronger effect was observed among the subset of
patients in the intervention group who had poorer baseline levels and
among the most disadvantaged populations compared with their
counterparts.
An Italian evaluation of the clinical effectiveness of a program,
SINERGIA, was designed to help stable patients manage their type 2
diabetes, thereby decreasing unnecessary demand on limited spe-
cialist resources and contributing to a sustainable health system.45
The rationale for this study is interesting in terms of aiming at re-
ducing unnecessary demand for physicians. It posits that if patients
with stable diabetes can be empowered to self-manage their disease
through this patient-focused intervention, then expert clinical per-
sonnel can be freed to serve sicker patients. The intervention con-
sisted of nurse- and dietitian-led education, remote monitoring, and
electronic medical records. Patients were provided expert guidance to
develop their own therapeutic goals, recognize the significance of
their symptoms, monitor their glucose level, manage emergencies
that may arise, improve their life style, and deal with diabetes-related
problems. In total, 1,004 patients with type 2 diabetes were recruited
into the SINERGIA program. The impact of the program on patient
self-management was followed up for a median of 12 months (range,
6–24 months). The most significant findings were a very substantial
decrease in A1c level, from 10.5% to 4.3%, as well as a decrease in
personal visits, from 2.8 to 2.3 per year. Thus, the authors concluded,
‘‘The SINERGIA model is effective in improving metabolic control
and major cardiovascular risk factors, while allowing ‘‘diabetologists
to dedicate more time for patients with more acute disease.’’45
A third study was conducted in The Netherlands with a unique
focus on the effects of cognitive behavioral therapy delivered via the
Internet on depression and glycemic control.46 This was an RCT with
a sample of 255 adult diabetic (type 1 or 2) patients with elevated
depression symptoms. After a period of only 1 month, the inter-
vention proved to be effective in reducing these symptoms, but it had
no effect on A1c. However, the findings cannot be considered reliable
because of the very short duration of the study.
The fourth study was conducted in France in 2011 with a follow-
up in 2014. The initial study47 was a 6-month RCT conducted in 17
sites throughout France with the aim of evaluating the efficacy of
a smartphone application coupled with an Internet system (Diabeo)
for metabolic control among adult patients with type 1 diabetes
(n = 180).
The Diabeo system consists of a personalized bolus calculator that
takes into account the patient’s glucose targets, amount of carbo-
hydrate consumed, premeal glucose value, and anticipated physical
activity. It has an automated algorithm that recommends adjustment
in insulin-to-carbohydrate ratios and basal insulin, data transmis-
sion capability, and a secure Web site for telemonitoring and tele-
consultation. Patients were randomly assigned to three equal groups:
(1) usual care consisting of quarterly follow-up clinic visits, (2)
smartphone with Diabeo and quarterly visits, or (3) smartphone with
Diabeo and access to teleconsultations every 2 weeks but no medical
office visits. The primary end point was the difference in A1c level at
6 months among groups. Use of Diabeo with teleconsultation (Group
3) resulted in a 0.9% reduction in A1c level compared with controls
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(Group 1) and a 0.7% reduction in Group 2. There was no difference in
the rate of nonsevere hypoglycemia among groups at end point.
Additionally, there were no differences among the three groups in
terms of the time spent in face-to-face visits or in telephone con-
sultations. Patients in Groups 1 and 2 spent more time traveling to
and from hospital visits compared with those in Group 3, thereby
demonstrating an added benefit for patients using Diabeo with tele-
consultation. The authors concluded that the Diabeo system signifi-
cantly improved glycemic control in patients with type 1 diabetes
with less medical time and at less cost to the patient compared with
controls.
A post hoc subanalysis of the data from this study48 was published
in 2014. Its purpose was to ascertain the role of the Insulin Dose
Advisor (IDA) in Diabeo and telemedicine support in reducing A1c
levels. High users (n = 56) and low users (n = 57) in Group 2 and Group
3 were identified using median ‘‘informed meals’’ consumed (defined
as when the system proposed an appropriate insulin dose). For ‘‘high
users,’’ informed meals remained stable throughout the 6-month
study period, whereas they declined among ‘‘low users.’’ A1c levels
declined among ‘‘high users’’ from 8.7% to 8.2%. ‘‘Low users’’ also
experienced A1c reduction, from 9.0% to 8.5%. Patients receiving
teleconsultation support tended to show greater improvement, but
the difference was not statistically significant. The subgroup analysis
suggested that frequent communication with healthcare profes-
sionals among ‘‘low users’’ may have contributed to the A1c im-
provement. The authors concluded that ‘‘the Diabeo system improved
glycemic control in both high and low users who avidly used the IDA
function, while the greatest improvement was seen in the low users
who had the motivational support of teleconsultations.’’48
Four studies meeting the inclusion criteria for analysis were
published in 2012. With one exception, all were conducted in the
United States.
Beginning in 2006, the New York City Health and Hospitals Cor-
poration initiated HouseCalls, a diabetes-telehealth program in
conjunction with its Medicaid Health Plan. Patients with poorly
controlled type 2 diabetes (A1c > 7%) were referred to the program.
This descriptive observational study (single group/no controls) was
based on the experience of 330 patients enrolled in HouseCalls for a
2-year period (2008–2009) and published in 2012.49 These patients
were given in-home monitoring devices including glucose meters
and blood pressure monitors (for patients with hypertension), each
connected to a telemonitoring modem. Patients were trained to take
readings, upload the information, and transfer the data to a secure
Web site. Readings were monitored by a telehealth nursing team.
Automated ‘‘high alerts’’—when certain values were exceeded—re-
sulted in calls by nurses within a 2-h period on weekdays. Nurses
tracked and managed patients’ status, documented care plans, and
recorded communications with patients’ primary care physicians.
Average change in A1c for the entire population over a 12-month
assessment was 1.8%. This was both statistically and clinically sig-
nificant. Patients who completed the program had a larger reduction
(- 2.2% versus - 1.4%) in A1c compared with those who dropped out
of the program.
A U.S. RCT (n = 415) was designed to determine whether a multi-
faceted intervention would help patients with uncontrolled type 2
diabetes (initial online publication was in 2012).50 The intervention
consisted of seven components: (1) an automated wireless upload of
glucose readings with graphical feedback, (2) a status summary re-
port, (3) nutrition and exercise logs, (4) insulin record, (5) team
messaging, (6) advice by care manager and dietitian, including
medication management, and (7) personalized education by video.
Glycemic control was the primary outcome. After 6 months, patients
in the intervention group ‘‘achieved greater decreases in A1c as
compared to those in the usual care group, but the differences were
not sustained at 12 months.’’50 The authors attributed this finding to
‘‘significant improvements in the usual care group in [this] setting.
More patients in the intervention group achieved clinically mean-
ingful improvement in A1c than the usual care group.’’50 In other
words, both groups experienced improvements in their blood glucose
levels, but the intervention group experienced greater improvement.
Other significant differences were observed between the two groups
favoring the intervention, including medication management
(number of medication orders and number of insulin orders). There
were no differences in the number of physician visits made by the two
groups during the 12-month study period.
A study of adolescents with poor metabolic control (diabetes type
1 or 2) conducted an RCT (n = 146) to ascertain whether a tailored,
intensive, home-based, multipart treatment program was superior to
weekly telephone support in terms of adherence to prescribed regi-
men.51 The intervention group received a complex multipart regimen
that promoted self-management across family, school, and com-
munity settings through intensive patient, caregiver, and peer edu-
cation and training. The control group received telephone support
only. It should be noted that sample size was slightly below 150.
Nonetheless, we include this study in this analysis because it focused
on a population of interest—namely, adolescents with type 1 or type 2
diabetes and poor metabolic control. Most of the patients were Af-
rican American and living in single-parent families. The mean A1c
value at baseline was 11.7%. However, results showed substantial
improvement in glycemic control (a decrease of 1.01% at 7 months
and 0.74% at 12 months compared with those receiving telephone
support only). Moreover, when asked, the parents of these adoles-
cents reported significant improvements in their children’s adherence
to diabetes management such as insulin and dietary management,
blood glucose monitoring, and symptom response.
A prospective record analysis of 1,000 patients in India with type 2
diabetes was published in 2012.52 The intervention consisted of a
Diabetes Telemanagement System in which a team of physicians,
educators, dietitians, nurses, pharmacists, and psychologists pro-
vided monitoring functions as well as educational programming and
customized guidance for patients in the program. The team main-
tained electronic records for the patients that included detailed
medical history, target glucose values, and life style factors. Each
patient was given three options for follow-up care: telephone, e-mail,
or secure Web site. Advice was provided on a patient-specific, ‘‘as
needed’’ basis. After 6 months, patients in this cohort experienced
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improvement in A1c, blood pressure, LDL cholesterol, and total
cholesterol. However, this study did not use any controls to ascertain
whether the changes could be fully attributable to the intervention.
In 2013, three published studies met the inclusion criteria for this
analysis, one each from Taiwan, the United States, and Korea. They
are reported here in that order.
A longitudinal case-control study of the effects of online self-
management education and telemedicine on the adoption of seven
self-care behaviors was conducted in Taiwan (n= 162).53 The patients
had either type 1 or type 2 diabetes without severe complications. The
intervention consisted of a third-generation mobile telecommunica-
tions glucosemeter, an online diabetes self-management system, and a
teleconsultation service. It enabled the patients to see online their
glucose test results, blood pressure values, body weight, insulin in-
jection record, and daily diet and physical activity. Outcomes were
measured in terms of physical activity level, diet, medication com-
pliance, coping skills, problem-solving abilities, risk reduction, and
glucose monitoring compliance. Fifty-nine patients participated in the
study, and theywerematched by demographic characteristics with 103
who did not. After 18 months, patients in the intervention group were
more likely than those in the matched control group to adopt healthy
behaviors in five areas: physical activity, diet, medication compliance,
coping, and problem solving. In addition, they were more likely to
monitor their blood glucose compared with their counterparts.
A somewhat related study on the differential receipt (i.e., who does
and who does not receive) of diabetes education was conducted in the
United States.54 The analysis was based on data from the National
Medical Expenditure Survey (n = 1,797). All subjects had type 2 di-
abetes. Results from a logistic regression revealed that being African
American increased the likelihood of receiving diabetes education.
However, the opposite trends were observed among residents in rural
areas and those without health insurance, as well as those living in
the South. Perhaps more important is that the majority of the sample
(63.7%) reported not receiving any diabetic education. Thus, on a
national scale, only 6.3% of persons with diagnosed type 2 diabetes
reported having received diabetes education on the telephone.
A novel approach for predicting BMI from voice signals was in-
vestigated in Korea in 2013.55 The investigation was based on a
sample of 1,568 subjects divided into four groups by age (20–40 and
40–60 years) and gender. Logistical regression analysis of the data
revealed significant statistical differences among the four groups in
terms of diagnosing BMI from voice signals. The authors concluded
that their ‘‘results could support the development of BMI diagnosis
tools for real-time monitoring.’’55
VHA Studies
Several studies were conducted at the VHA on this topic.56–65 Of
these, five were reported by the same senior author with different co-
authors. These VHA studies are presented here in historical order as a
set, shown in Table 3.
An observational study (n = 445) of the effects of the Care Co-
ordination Home Telehealth program on use of service and quality of
life was conducted among patients in the South Florida–Puerto Rico
and Georgia VHA region (published in 2005).56 The authors pointed
out that diabetes was the second most prevalent condition among
veterans in this region and that ‘‘4% of the population (more than 1
million veterans, nationwide) were consuming 40% of the healthcare
resources.’’56 The analysis of utilization data was based on admin-
istrative records, starting at baseline and after 12 months of partic-
ipation in the program. There was no comparison group. In total, 537
patients were recruited to participate in the study. Of these, 92 were
lost to follow-up for various reasons, thereby leaving a sample of 445
for analysis. Those who dropped out had poorer health and dimin-
ished social functioning compared with those who remained. An
‘‘intent to treat’’ analysis was conducted with the assumption that
those who dropped out would have no improvement in any of the
outcome measures. A logistic analysis for binary outcomes (used or
not used service) and a Poisson regression were used. The results
indicated ‘‘a statistically significant reduction in the proportion of
patients who were hospitalized (50% reduction), emergency room use
(11% reduction), reduction in the average number of bed days of care
(an average of 3 days, as well as improvement in Health Related
Quality of Life, physical functioning, bodily pain, and social func-
tioning.’’56 However, the authors cautioned that ‘‘the results need to
be interpreted with caution because we used a single-group study
design that may be influenced by regression to the mean ..’’56
Chumbler and co-workers published three articles in 2005,56,57,59
one in 2006,58 and one in 2004,60 each with different objectives but
all using a case-control study design. A retrospective case-control
study design compared 400 diabetes patients with complex medi-
cation regimen and at high risk for expensive, multiple inpatient and
outpatient services (including emergency department visits) with a
matched group of 400 who did not receive the intervention.57 Elig-
ibility for inclusion in the study included two or more hospitaliza-
tions or emergency visits during the preceding 12 months. Patients in
the intervention group were enrolled in the patient-centered Care
Coordination Home Telehealth program. ‘‘Twelve months after en-
rollment there was a significant difference between the treatment and
comparison groups.’’57 Need-based and ‘‘just in time’’ visits increased
in the treatment group whereby their glycemic level was controlled,
but such visits and their attendant benefits decreased in the com-
parison group. On the other hand, the treatment group ‘‘had a lower
likelihood of having 1 or more hospitalizations than patients in the
comparison group.’’57 The treatment effect was measured on the basis
of difference-in-differences, which constitutes the net difference
between the differences between the two groups, before and after
treatment.
In a 2-year follow-up of the same groups,58 the treatment group
‘‘exhibited a statistically significant reduction in the likelihood of all-
case and [diabetes-related] hospitalization.’’ The same results were
observed after the authors controlled for selection bias and inter-
vening time factors. The intervention resulted in reducing ‘‘avoidable
healthcare services.’’ This study was published in 2006.
Also in 2005, Chumbler et al.59 evaluated the effects of twomodalities
of diabetes management for patients who required close monitoring.
Group 1 was monitored weekly with intensive evaluations (n = 197),
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whereas Group 2 was monitored daily but less intensively (n = 100).
The first modality consisted of patients with active diabetic wounds
who were monitored by a care coordinator on a weekly basis in an
intensive program. The second group consisted of elderly patients
with diabetes, many of whom had wounds that also required close
monitoring. These were monitored daily in a less intensive program,
while they received general instructions on diabetes care and met-
abolic control through a home messaging system. A nurse coordi-
nator monitored their symptoms and needs. Telemonitoring in both
groups consisted of (a) a hand-held in-home messaging device with
disease management dialogues, (b) a telemonitor with two-way
audio–video connectivity, and (c) a videophone. Patients in the in-
tervention group were required to answer few questions on a daily
basis using the hand-held device. The care coordinator reviewed the
data daily. The catchment area was South Georgia and North Central
Florida. Patients who had two or more hospitalizations in the pre-
ceding year were eligible for participation. However, they were not
randomly assigned to the two groups.
At baseline, Group 1 was younger and more likely married than
those in Group 2. They also had a substantially lower hospitalization
history than their counterparts (30% versus 63%). After 12 months,
‘‘the proportion of one or more hospital admissions and number of
bed days of care decreased in the daily monitoring group, and in-
creased in the weekly monitoring group, more or less doubling in the
former and being halved in the latter.’’59 No differences in clinical
outcomes were observed between the two groups. The results from
this study are not conclusive mostly because of selection bias, but the
findings suggest that daily monitoring was more effective in reduc-
ing hospitalization compared with weekly monitoring.
In 2004, an earlier study was conducted in the same VHA service
area used a case-control design to assess the effects of telemonitoring
for patients with hypertension, diabetes, respiratory disease, and/or
heart disease.60 A sample of 111 frail, elderly patients was matched
with 115 such patients. The results of the study suggest that care
coordination can improve functional independence among nonin-
stitutionalized patients with chronic disease. However, because of the
performance date of this study it is not included in the analysis of
empirical findings.
Another RCT in 2010 (n = 150 type 2 diabetes patients) was con-
ducted at the VHA in Pennsylvania. It investigated the effects of an
active nurse-led medication management with home telemonitoring
(via monthly telephone calls) on glycemic control, blood pressure,
and body weight.61 All patients in the study were already on a
medication regimen. Those in the intervention group were asked to
Table 3. Telediabetes and Outcomes in Veterans Health Administration Studies
OUTCOMES AND EFFECTS
REFERENCE (YEAR)
RESEARCH
DESIGN
SAMPLE
SIZE A1C BP LIPIDS WEIGHT COMMENTS
Chumbler et al.56 (2005) Observational 445 NM NM NM NM Hosp. Y(50%); ER Y(11%); bed-days Y 3 days; QoL [;
physical and social functioning [; bodily pain Y;
used ‘‘Intent to treat’’
Chumbler et al.57 (2005) Retrospective
case-control
800 Y A1c=YHosp. NM NM NM Visits [, Hosp. Y(correlates with A1c)
Barnett et al.58 (2006) Retrospective
case-control
800 Y NM NM NM Avoidable healthcare services Y. If A1c Y, then
hospitalization and primary care visitsY.
Chumbler et al.59 (2005) Record review 297 O O O O After 12 months Hosp. rate Y33% with daily
monitoring. But, BP and BMI baseline
significantly worse for Tx group
Stone et al.61 (2010) RCT 150 Y O Y O Both groups improved but intervention group greater
Wakefield et al.62 (2011) RCT 302 Y at 6 months Y NM NM A1c difference at 6 months but disappeared at
12 months. Ongoing education, advice, and
surveillance improved clinical outcomes. Control A1c
significantly improved at 12 months.
Wakefield et al.63 (2012) Survey 302 Y at 6 months Y NM NM Knowledge, self-efficacy, adherence, and patient
perceptions, no difference among Low Tx, High Tx,
and Control (except knowledge at 6 months only)
Chumbler et al.64 (2009) QE 774 NM NM NM NM Mortality Y 7%
Powers et al.65 (2009) CR 528 Y O Y O
A downward arrow indicates down or decreased; an upward arrow indicates up or increased.
A1c, glycated hemoglobin A1c; BMI, body mass index; BP, blood pressure; ER, emergency room; Hosp., hospitalization; NM, not measured; O, no difference; QoL, quality of
life; RCT, randomized clinical or controlled trial; Tx, treatment; VHA, Veterans Health Administration.
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monitor their blood glucose, blood pressure, and weight on a daily
basis and to transmit these data to the clinic via a secure network. In
addition, they received monthly calls by the nurse for diabetes ed-
ucation and self-management review. Blood glucose, blood pressure,
and weight measures were taken at baseline, 3 months, and 6 months
for both groups. Although both groups had improved glycemic
control, the intervention group had ‘‘significantly larger decreases in
A1c at 3 and 6 months with most improvements by 3 months’’61
compared with the control group.
Two separate articles were published in 201162 and 201263 stem-
ming from a study that was conducted at the VHA Medical Center in
Iowa. This was an RCT (n = 302), nurse-managed telemedicine pro-
gram. Patients were provided with a home device for manually en-
tering blood pressure and blood glucose measurements. Patients with
type 2 diabetes and hypertension were assigned randomly into three
groups: (1) usual care, (2) low-intensity program, and (3) high-
intensity program. The high-intensity group received health informa-
tion tips on diet, exercise, smoking cessation, foot care, medications,
weight measurement, and lifestyle adjustments. The low-intensity
groupdid not receive this information, but both groupswere required to
send blood glucose and blood pressure measurements and answer two
questions daily.
The first report (published in 2011)62 focused on glycemic level
(A1c) and systolic blood pressure, whereas the second (published in
2012)63 focused on diabetes knowledge and medication adherence.
Overall, patients in both intervention groups had improved A1c
during the first 6 months of the study compared with the control
group, but this difference disappeared after 12 months. However,
patients in Group 2—those who received health information tips—
maintained the difference after 12 months, thereby suggesting the
importance of education in glycemic control. Moreover, patients
receiving the high-intensity intervention had a significant decrease
in blood pressure compared with those in the low-intensity and usual
care groups. This difference occurred at 6 months and was main-
tained after 12 months. In terms of secondary outcomes, no signifi-
cant differences were observed ‘‘across the groups in self-efficacy,
adherence or patient perceptions of the intervention modes.’’63 The
authors concluded that ‘‘home telehealth can enhance detection of
key clinical symptoms that occur between regular physician visits.’’63
A case-control study was conducted to assess mortality risk among
patients with diabetes (type unspecified) who were enrolled in the
VHA Home-based Care Coordination Telehealth program (from June
2004 to December 2005 and published in 2009).64 The intervention
consisted of an automated electronic messaging device that queried
patients about their diabetes symptoms and general health on a daily
basis. The device was connected to a regular telephone line moni-
tored by nurse coordinators. When conditions warranted, nurses
called patients for follow-up, to make referrals, and to help with
medication management. They consulted with physicians about ad-
justing medications and scheduling appointments. A sample of 387
patients was enrolled in the program and observed for 4 years. The
cases were matched with 387 controls using a propensity score, a
summary measure of the patients’ background that represents the
probability of a patient belonging to the intervention group. Analysis
of the 4-year all-cause hazard mortality ratio showed lower mortality
in the intervention group compared with the control group (19%
versus 26%, respectively).
A related VHA study (RCT; n = 528) investigated the effects of ‘‘a
tailored hypertension self-management intervention’’ on A1c and
LDL cholesterol.65 The study was aimed at evaluating a hypertension
self-management program. This subanalysis investigated unintended
consequences in relation to A1c and LDL. It compared laboratory
values of a subsample of 216 patients with diabetes over a 2-year
period. The hypertension self-management had a spillover effect in
terms of controlling A1c by a margin of 0.46%, as well as a reduction
of 0.9mg/dL in LDL, but the latter difference was not statistically
significant.
IDEATel Reports
IDEATel was a large RCT (n = 1,655), of long duration (up to 5
years), and its investigators produced a prolific record of 18 publi-
cations,66–83 starting in 2002, all from the project (shown in Table 4).
It seemed appropriate to discuss all reports of findings pertaining to
this project as a single set. These are presented here in historical order.
The initial two articles from IDEATel were published in the same
issue of the Journal of the American Medical Informatics Association
in 2002. The first66 described the technical implementation of the
project, and the second67 described the research methodology. These
will not be included in this analysis because they were descriptive in
nature, and the relevant information they contained regarding pro-
ject design, rationale, and research methods have been repeated in
subsequent publications.
This project was conducted in two sites: an urban region in New
York City and a rural region in Upstate New York State. In both
places, all patients were Medicare beneficiaries residing in medically
underserved areas and using a Federally Qualified Health Center.
The research was undertaken by a consortium based at Columbia
University.
Patients who had type 1 or type 2 diabetes were allocated ran-
domly as clusters to either the telemedicine or usual care group based
on their primary care provider. This probably implies that all patients
of a given provider were allocated to either the experimental or the
control group. Hence, greater variability within the cluster would
result in a smaller sampling error—or better representation—and vice
versa. Participants in the intervention group received a home tele-
medicine unit specifically developed for the project, consisting of a
Web-enabled modem connected to a telephone line with four com-
ponents: videoconferencing, a remote glucose monitoring device, a
Web portal for patients with access to their own clinical data and to a
nurse case manager, and an educational Web site developed by the
American Diabetes Association. Nurse managers were trained in di-
abetes management and information technology. Each intervention
subject was assigned a case manager who worked under the super-
vision of diabetologists. The protocols were based on the Veterans
Administration’s ‘‘VA/DoD Clinical Practice Guideline for the Man-
agement of Diabetes Mellitus in Primary Care.’’84 Initial plans called
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Table 4. Informatics for Diabetes Education and Telemedicine Findings (IDEATel)
METHODOLOGY
REFERENCE (YEAR) SAMPLE SIZE RESEARCH DESIGN FINDINGS COMMENTS
Shea et al.68 (2006) 1,665 (C= 821;
I = 844)
RCT After 1 year, A1c Y, BP Y, LDL Y A1c improved in both groups, more
in intervention group
Trief et al.69 (2006) 1,578 RCT prospective
analysis
Weak relationship between depression
and A1c but did not predict change
in glycemic control
Palmas et al.70 (2006) 1,040 Clustered
randomization
Ambulatory pulse pressure may help predict
albuminuria progression.
Trief et al.71 (2007) 1,665 RCT Psychosocial outcomes[ Possible spillover effect from education
and consultation; not sure about
generalizability of findings
Izquierdo et al.72 (2007) 338 (IV group) Observational Identification of (1) inappropriate medication,
(2) inappropriate timing, (3) contraindication
to current medication, and (4) adverse events
Tudiver et al.73 (2007) 116 Provider survey Acceptance [, perceived patient knowledge[ Patient activation [, excessive paperwork;
conflicting advice within team
Shea et al.74 (2009) 1,665a RCT A1c Y, LDL Y, BP Y, mortality O 5-year follow-up, high dropout numbers;
used intention-to-treat
Lai et al.75 (2009) Similar to Robinson et al.78 (2010)
Izquierdo et al.76 (2010) 890 Within cluster
randomization
Knowledge [, exercise [, WC Y, BMIY 2 years in their analysis; women
reduced WC
Palmas et al.77 (2010) 1,665 RCT No effect on cost Cost of implementing program high,
need to lower cost of equipment
by $622/month/case
Robinson et al.78 (2010) 109 Survey In-home training preferred Preferences for training
Weinstock et al.79 (2011) 1,650 RCT Physical decline Y, more PA (i.e., reduced rate
of decline in impairment); improved task
performance
Learning curve; remote training is
effective; PA associated withY comorbidity,
Y depression, [ social networking, Y BMI,
Y A1c (pedometers)
Weinstock et al.80 (2011) 1,665 RCT A1c Y Telediabetes can reduce disparities;
BMI not associated with A1c. Hispanics
had highest A1c at baseline and greatest
improvement.
Luchsinger et al.81 (2011) 2,169 (type 2) RCT Slower cognitive decline Mediated by decline in A1c, not A1c or
LDL; post hoc analysis
Shea et al.82 (2013) 1,665 RCT Comorbidity Y, adherence [ Low SES, also worst A1c; lowest-income=
more benefits in A1c and BP;
Lowest education=more benefits
in A1c and BP
Trief et al.83 (2013) 1,665 RCT Self-reported adherence improved Whites more adherent than Hispanics
or African Americans
A downward arrow indicates down or decreased; an upward arrow indicates up or increased.
aSee comments.
A1c, glycated hemoglobin A1c; BMI, body mass index; BP, blood pressure; C, control group; I, intervention group; LDL, low-density lipoprotein; O, no difference; PA,
physical activity; RCT, randomized controlled trial; SES, socioeconomic status; WC, waist circumference.
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for a total sample of 1,500 to provide adequate statistical power for
subgroup analysis. This was increased during enrollment to com-
pensate for early differential dropout rates, which were larger in the
intervention group (248 out of 1,665: 144 from the intervention
group and 104 from the control group). About 90% of all patients
were 70 years of age or older.
A synopsis of the main findings from empirical analysis of data
that were based on this project is shown in Table 4. The following is a
discussion of these findings.
The first set of three research articles was published in 2006. The
first article68 reported the results of the intervention on health out-
comes after 1 year of observation. The results showed a positive trend
in terms of improved glycemic control, blood pressure, and LDL
cholesterol among patients in the experimental group. The second
article69 had a different focus, and it investigated the relationship
between clinical depression and glycemic control. A weak relation-
ship was observed between these two variables. However, the pres-
ence of depression did not predict change in glycemic control in
either the control or experimental group. The third article70 was
concerned with clinical predictors of glycemic control after 2 years
from baseline. The researchers discovered ‘‘that ambulatory pulse
pressure [but not office pulse pressure] improves the prediction of
increased urine albumin excretion in older people with type 2 dia-
betes.’’70 The importance of this finding lies in the fact that ‘‘ambu-
latory monitoring appears to provide information above and beyond
that provided by office blood pressure measurements.’’70
Subsequently, a set of three articles from the project was published
in 2007 from the project. The first71 was focused on the effects of the
intervention on psychosocial outcomes, after 1 year of follow-up.
This analysis was based on the expectation (hypothesis) that a sup-
portive relationship between the patients and knowledgeable pro-
viders will likely benefit the patients’ emotional well-being. Here, the
authors concluded that the intervention ‘‘resulted in significantly
improving diabetes self-efficacy..’’71 However, it did not improve
depression or diabetes distress. Diabetes self-efficacy was not ex-
plicitly defined. It probably referred to how patients felt about their
diabetes. The second article72 in this set was concerned with the
incidence of medically urgent situations, but only on the part of
patients in the intervention group. In other words, there was no
control group comparison in this analysis. Based on 3 years of
follow-up, 67 medically urgent situations were encountered among
338 patients. All were successfully identified and remediated. This
success was attributed to improved communication between pri-
mary care providers and their patients as well as improved access to
diabetes care. The third article73 was a report from a survey (n = 116)
of the primary care providers who cared for the patients in this
project. It was conducted at 12 and 24 months from baseline. The
findings from the survey revealed that providers were generally
supportive of telemedicine and that they were sanguine on its
positive impact on their patients. Nonetheless, these providers were
also concerned about excessive paperwork and duplication, as well
as conflicting advice and management decisions regarding indi-
vidual patients.
In 2009, two research articles were published from this project. The
first74 reported clinical results based on 5 years of follow-up. How-
ever, because of the long time frame, substantial numbers had
dropped out (358 from the intervention group and 514 from the
control group). The authors used ‘‘intention-to-treat’’ analysis in
order to retain the original sample size, by imputing data for those
who dropped out. This analysis revealed net improvements in gly-
cemic control, LDL cholesterol, and blood pressure. The second ar-
ticle75 was an evaluation of a remote educational program that was
included under the umbrella of this project. According to the authors,
this educational tool resulted in ‘‘significant improvements in their
[patients] ability to perform tasks on their home telemedicine unit.’’75
In other words, patients who received this education were better able
to use their telemedicine units.
Four articles were published from this project in 2010.
The first article76 in this set was focused on body weight (waist
circumference and body mass index). Patients in the intervention
group were connected to a dietitian or nurse via their home video-
conferencing equipment, and the dietitian or nurse recommended
lifestyle andmedication changes, as indicated in each case, every 4–6
weeks. It is not surprising that, after 2 years, patients in the inter-
vention group improved their knowledge of diabetes risk factors and
their actual bodyweight. Women fared better thanmen in this regard.
The second article77 was based on data analysis from Medicare
claims over 6 budget years. Medicare claims data were similar in the
two groups. However, the authors pointed out that the intervention
would not be cost-efficient since ‘‘the cost of implementing the
telemedicine intervention was high, largely representing specific
purpose hardware and software costs required at the time. Lower
implementation costs will need to be achieved using lower cost
technology in order for telemedicine case management to be more
widely used.’’77
The third article78 was focused on a very specific issue—namely,
why patients may request additional training and their preference of
delivery mode of such training. Here, a total of 109 patients from the
entire group requested additional training. Of the three options of-
fered to them—in-home visit, unassisted use of user’s manual, and
telephone training—the majority preferred in-home training.
The fourth article79 (initial online publication was in 2010) in-
vestigated the effects of the intervention on physical activity and
impairment. The intervention group experienced a lower rate of
decline in physical activity and impairment compared with the
control group. Hence, the authors suggested that ‘‘pedometers may be
a helpful inexpensive adjunct to diabetes initiatives delivered re-
motely with emerging technologies.’’79
Two research reports from this study were published in 2011.The
first80 was concerned with socioeconomic disparities, particularly
ethnicity. It reported that glycemic control improvement was noted
among ‘‘Hispanics, who had the highest baseline A1c levels.’’80 The
second81 was an analysis of the differences in cognitive outcome
between the intervention and control groups. The authors reported ‘‘a
slower cognitive decline in the intervention group, mostly as a result
of improvement in A1c.’’81 This is an interesting finding as it suggests
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a link between A1c and cognitive decline. Moreover, sicker Hispanic
patients paid more attention to their A1c than their counterparts.
In 2013, two reports were published from this study. The first82
investigated whether the intervention had an effect on socioeco-
nomic disparities (as measured by income and education) and eth-
nicity. The results from this analysis revealed that participants of
lower socioeconomic status (SES) ‘‘benefited at least as much as
higher SES’’82 counterparts. However, limited variations in income
did not permit an analysis of the full impact of SES. Average annual
income in the entire sample was about $15,000. The other analysis83
investigated differential adherence to prescribed regimens, including
glucose testing, diet, exercise, and foot care, and also whether ad-
herence mediates glycemic control. In this case, adherence improved
glycemic control. Overall, members of minority groups never
achieved the same level of self-care as whites.
GDM
GDM is a glucose intolerance that occurs during pregnancy, typ-
ically at around week 24. It may or may not antedate pregnancy, and
it may not necessarily continue after delivery. In other words, preg-
nant women without a history of diabetes may develop high blood
glucose levels during pregnancy. GDM affects the mother’s health as
well as that of the baby. It can lead to macrosomia (fat baby), hy-
poglycemia, or low blood glucose and a higher risk for breathing
problems and subsequent type 2 diabetes. Babies with macrosomia
face a higher risk for obesity and type 2 diabetes, as well as breathing
problems, low blood glucose levels at birth, and damage to their
shoulders during the birth process.
Based on diagnostic criteria by the International Association of
Diabetes in Pregnancy Study Groups, GDM affects 17.8% of preg-
nancies.85 This is nearly double the rate (9.2%) at which pregnant
women are currently diagnosed as having GDM.86 The difference
between the two estimates derives from the diagnostic threshold for
defining GDM. The more liberal definition has the benefit of
alerting pregnant women to potential problems, and hence it may
lead to preventing some cases of shoulder dystocia and birth injury
by corrective actions such as weight control. Indeed, excess weight
in the offspring of women with GDM can be ameliorated with ap-
propriate therapy.87 Another estimate indicates that approximately
6–7% of pregnancies in the United States are complicated by dia-
betes and that approximately 85% of these cases represent women
with GDM.88
The causes of GDM are not fully known. The prevailing view points
to insulin resistance in the placenta. Hormones from the placenta
help the baby develop. But, these hormones can also block the action
of the mother’s insulin, which makes it hard for her body to use
insulin. When this happens, the mother’s pancreas works overtime to
produce insulin, but it would still be unable to lower blood glucose
levels. She may need up to three times as much insulin. Although
insulin does not cross the placenta, glucose and other nutrients do.
The extra glucose going through the placenta gives the baby high
glucose levels. This causes the baby’s pancreas to produce extra in-
sulin to maintain normal glycemia. Because the baby is getting more
energy than he or she needs to grow and develop, the extra energy is
stored as fat.
Without adequate insulin, glucose cannot leave the blood and be
changed to energy. Glucose builds up in the blood to high levels, or
hyperglycemia. The risk of GDM is associated with older age, higher
body weight, and family history.89
GDM affects the mother after the baby’s body has been formed, but
while the baby is growing. Because of this, GDM does not cause the
kinds of birth defects sometimes seen in babies whose mothers had
diabetes before pregnancy.
GDM is diagnosed using one step (75-g OGTT) or two steps
(screening using the 40-g glucose challenge, followed by a 100-g
OGTT for those who screen positive). The specific glycemic goals
should be specified for each individual, typically aimed at achieving
the following levels:
. Before a meal (preprandial): 95mg/dL or less
. 1 h after a meal (postprandial): 140mg/dL or less
. 2 h after a meal (postprandial): 120mg/dL or less
The optimal treatment for GDM includes glucose monitoring, diet
and exercise, oral diabetes medications, and initiation and titration of
insulin, as indicated, to maintain glucose targets.
The Cost of GDM
A report published in 2009 estimated the national costs associated
with GDM for 2007.90 Average expenditures for GDM were estimated
at $3,305 per pregnancy and an additional $209 in the newborn’s
first year of life. About 36% of this cost is covered by public programs
(mostly Medicaid), 56% is covered by private insurance, and 8% are
self-pay charity.90 However, the authors explained that these esti-
mates are limited to ‘‘near-term medical costs, omitting the increased
risk for long-term sequelae.’’90 Long-term costs are much greater
than those of the near term. As an indication of that cost, it may be
appreciated that 20% of babies born to mothers with GDM will be
overweight at birth and thus also have an increased risk for type 2
diabetes and cardiovascular disease91 (see also Kim et al.92).
Several highlights from a statistical brief from the Agency for
Healthcare Research and Quality demonstrated the added hospi-
talization costs among women with GDM. For instance, in 2008
‘‘one-third (33.9% of hospital stays with pre-existing diabetes com-
plicating pregnancy involved no delivery..) This compares with
10.3 percent of stays without diabetes..’’88 About two-thirds of
women with diabetes complicating pregnancy delivered via cesarean
section. The rate for women with GDM was 45.6%. ‘‘From 1997 to
2007, there was a 14% increase in the number of [hospital] stays
for all deliveries. In contrast, deliveries involving gestational dia-
betes increased 75%..’’88 The average hospital cost for women
without diabetes was $3,800, for women with preexisting diabetes
was $5,900, and for women with GDM was $4,500. Overall, ‘‘total
costs of hospitalization for all diabetes in pregnancy was over $1.4
billion..’’88
An estimate of maternity care and costs in Ireland among 4,372
women, of whom 354 had GDM, indicated a significantly higher level
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of emergency cesarean section, neonatal admission, and 34% higher
costs.93 Similar findings were reported in an RCT (n = 848) in 2012 in
Finland.94 ‘‘The cost of inpatient visits was 44% higher and neonatal
intensive care unit use was 49% higher in the GDM group than
among women without GDM.’’94
The Telemedicine Intervention in GDM
The telemedicine intervention in GDM is the same as that in
type 1 and type 2 diabetes. It consists of a structured electronic
system for monitoring, communication, and coordination be-
tween patients with GDM and their care providers. Despite some
variation in technical design and configuration, the system is
intended to provide connectivity for pregnant women with GDM
from their homes, places of work, or while traveling. It serves
four functions: (1) ongoing monitoring of blood glucose and re-
lated aspects, (2) clinical instruction, (3) medication titration and
compliance, and (4) educational programming. Hence, it includes
the measurement, storage, and analysis of relevant data, as well
as the use of the information for dosage adjustment of hypo-
glycemic medications for alerting patients when warranted, and
for providing counseling from nurses or dietitians in managing
blood glucose, appropriate exercise, and dietary intake. The an-
ticipated benefits are better adherence to medication, better
therapy adjustment, improved life style, and ultimately a healthy
and uncomplicated delivery.
Feasibility of GDM Telemonitoring
None of the studies that investigated the feasibility of tele-
monitoring GDM met the sample size criterion for inclusion in this
analysis. However, we chose three articles for brief discussion here.
All used the RCT design. These will not be considered when dis-
cussing the empirical evidence in this domain.
In 2007, a U.S. RCT (n = 57) investigated the use of an Internet
telemonitoring system to manage GDM among medically under-
served women.95 This study produced a modest finding—namely, that
‘‘women in the telemedicine group did experience enhanced feelings
of diabetes psychosocial self-efficacy.’’95 This may be translated
roughly to mean that women with GDM in the intervention group felt
better about their condition (or perhaps their ability to control it)
when compared with their counterparts. However, the feasibility of
using an Internet-based approach to manage GDM among poor inner
city women was obviously limited. The authors suggested that an
interactive voice recognition telephone link may have produced
better results.
In 2010, an RCT (n = 100) in Spain evaluated the feasibility of a
telemonitoring system for GDM based on the Internet and short
message service.96 ‘‘The system significantly reduces the need for
outpatient clinic visits (62%) and achieves similar pregnancy, de-
livery, and newborn outcomes.’’96 Among insulin-treated women,
there was an 82% reduction in outpatient visits.
In 2012, a U.S.-based RCT (n=80) demonstrated that adding inter-
active voice response to a telemonitoring system for pregnant women
with multiple medical conditions ‘‘increased system utilization and
contact between women with GDM and their healthcare providers.’’97
However, it had no impact on blood glucose values or infant birth
weight.97
GDM and Intermediate Outcomes
(Weight, Diet, Exercise)
Two studies meeting the criteria for inclusion in this analysis in-
vestigated the intermediate outcomes of telemonitoring GDM, in
terms of body weight, diet, and exercise. These were conducted in The
Netherlands (2011)98 and United States (2014).99 They are summa-
rized in Table 5.
In 2011, an RCT (n = 297)98 was conducted in The Netherlands that
investigated the predicted usage of a Web-based intervention aimed
at promoting healthy diet and physical activity. In total, 297 re-
spondents were recruited from various public sources, including
advertisements in local newspapers, postings in supermarkets, and a
health-related Web site. The sole inclusion criterion was BMI indi-
cating slight overweight (18.5–28.0 kg/m2), in addition to pregnancy.
The majority of those who agreed to participate were highly educated
women. These were randomly allocated in blocks of four to either the
intervention (n = 147) or control (n = 150) group. Both groups filled
out online questionnaires at the start of the project and 12weeks from
baseline. The intervention group received a Web-based lifestyle ap-
plication developed by The Netherlands Nutrition Center, whereas
the control group did not. The study produced several methodo-
logically relevant findings, but none substantive in nature: (1) Of
the 269 (in both experimental and control groups) who completed
the baseline questionnaire, only 159 filled out the posttest ques-
tionnaire (overall response rate of 59%). The response rate was
significantly lower in the intervention group (51% versus 66%).
Over one-third (or 36%) of respondents in the intervention group
did not use the application at all or as intended. (2) Nonetheless, as
expected, the users tended to be healthier and more knowledgeable
than the nonusers. Hence, those who had room for improvement in
terms of their diet and exercise were less likely to use the applica-
tion compared with their counterparts.
In 2014, a multistep formative evaluation was conducted to as-
certain the effectiveness of an e-intervention in preventing excessive
gestational weight gain.99 The technology consisted of aWeb site and
mobile phones. It was designed to maximize and sustain the use of
the system by the intended users. However, the development of the
clinical trial protocols followed an elaborate formative process, in-
cluding short interviews (n = 110), in-depth interviews (n = 24), and
focus groups (n = 26), all this to inform the study design. The authors
wanted to establish a theoretical foundation for linking intervention
features to observed outcomes that may result. In total, 1,689 par-
ticipants were randomized to an intervention group (n = 1,126) and a
control group (n = 563), at the rate of 2:1. Participants in both groups
had access to blogs, local resources, articles, and an information
guide to ‘‘frequently asked questions.’’ But, the intervention group
also had a weight gain tracker as well as diet and physical activity
goal-setting tools. In addition, they received customized reminders,
tailored content, and access to local community features. Use of the
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Internet among the participants was ‘‘comparable to those in other
weight studies of young adults and higher than reported in a pub-
lished study with pregnant women.’’99 The weight gain tracker was
used by the majority of the participants in the intervention group
(n = 705), but only 39% of this group actually set either diet or
physical activity goals.
GDM and Health Outcomes
Results from two studies (in Italy100 and United States,101 pub-
lished in 2009 and 2012, respectively) investigated the effects of
GDM telemonitoring on intermediate health outcomes, including
metabolic control, cesarean section, macrosomia, and referrals,
shown in Table 5.
The first was an Italian study (using sequential assignment to
intervention and control groups; n = 276) that investigated the ef-
fects of a telemonitoring system on metabolic and fetal outcomes
among women with diabetes.100 During enrollment in the study,
women were sequentially assigned to the intervention or control
group, but it was not clear whether the selection process was ran-
domized or not. The intervention group consisted of 88 women with
GDM. Of these, 17 had type 1 diabetes. The control group consisted
of 115 women with GDM; 15 of them had type 1 diabetes. Women in
the intervention group were trained to use a home glucose meter
and were asked to submit their blood glucose measures every week
and more often when necessary. They were also given a medical
examination once a month. Women in the control group received a
medical examination every 2 weeks but no glucose meters. Overall,
clinical values were comparable between the two groups. However,
those in the intervention group had better glycemic control in the
third trimester of pregnancy, fewer cesarean sections, and lower
rates of macrosomic infants, compared with those in the control
group. In addition, they expressed lower levels of frustration with
their condition.
The second study was a quasi-experiment published in 2012. It
was based on a large sample (n = 11,435) at Kaiser Permanente of
Northern California, an integrated health system that provides care to
over 3 million members in 14 counties.101 The study population was
limited to pregnant women with GDM, and the intervention consisted
of telephone counseling 7 days a week on glucose monitoring and
control, diet, and physical activity by registered nurses and dietitians.
Referred women received one or two counseling calls per week. They
could also initiate the calls themselves when they had questions or
concerns. The outcome measures (body weight, infant birth weight,
and use of insulin) were extracted from the medical records. The
Table 5. Tele-Gestational Diabetes Mellitus Outcomes
INTERMEDIATE OUTCOMES
REFERENCE
(YEAR) COUNTRY
RESEARCH
DESIGN
SAMPLE
SIZE WEIGHT
HEALTH
BEHAVIOR
HEALTH
KNOWLEDGE
E-HEALTH
ENGAGEMENT COMMENTS
Kelders et al.98
(2011)
The Netherlands RCT 297 O O O [ (64%) Most respondents were female
and highly educated; Web-based
intervention for diet and physical
activity
Graham et al.99
(2014)
United States Formative research
interviews
1,689 Y [ [ [ (85%) E-Moms ROC analyzed e-health
usage rather than vital sign change
(e.g., A1c, weight). Most appropriate
mix of online features and their
effectiveness predictors is unknown.
HEALTH OUTCOMES
REFERENCE
(YEAR) COUNTRY
RESEARCH
DESIGN
SAMPLE
SIZE STRESS MACROSOMIA A1C CESAREAN
POSTPARTUM
A1C TESTING COMMENTS
Dalfra et al.100
(2009)
Italy Sequential
assignment
276 Y *Y O (type 1);
Y(GDM)
Y [metabolic control Intervention group had less
frustration with DM; used CES-D,
SF-36, and Stress/Distress measure
to evaluate patients; QoL[; Role
Emotional score improved in UC
group only. Reduced number of
visits to clinic
Ferrara et al.101
(2012)
United
States
Quasi-
experimental
11,435 NM Y NM NM [ Referral to GDM telephonic nurse
management is effective.
A downward arrow indicates down or decreased; an upward arrow indicates up or increased.
A1c, glycated hemoglobin A1c; CES-D, Center for Epidemiologic Studies Depression Scale; DM, diabetes mellitus; e-Moms ROC, e-Moms of Rochester; GDM, gestational
diabetes mellitus; NM, not measured; O, no difference; QoL, quality of life; RCT, randomized controlled trial; SF-36, 36-item Short Form; UC, usual care.
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study design allowed an assessment of the association between re-
ferral to this program and the outcomes. The results suggest that
‘‘receiving care at the centers with the higher referral frequency to
telephonic nurse management for [GDM] was associated with de-
creased risk of macrosomic infants and increased postpartum glucose
testing.’’101
DR
DR is the result of damage to the blood vessels in the retina—the
image-processing layer of tissue in the back of the inner eye. The
main function of the retina is to convert the images into electric
signals and send them to the optic nerve of the brain.103 A healthy
retina is necessary for clear vision.
At an early stage, DR may not have any obvious symptoms. How-
ever, diabetes starts to damage the small blood vessels, especially those
inside the retina, during this stage. The damaged blood vessels can leak
between the retinal layers, causing further damage, which can be
manifest in the form of blood spots, macular edema (fluid leaking into
the central portion of the retina), which causes swelling and hence
blurring vision, or abnormal new blood vessel growth. As it progresses
to an advanced stage, the typical symptoms include blurry vision,
flashing lights, dark floaters, or limited peripheral vision.
Type 1 and type 2 diabetes are also associated with other eye
diseases, including cataracts (clouding of the lens of the eye), dry
eyes, and glaucoma (pressure build-up in the eye that damages the
optic nerve).
DR usually affects both eyes. If left untreated, DR can develop in
stages marked by different degrees of small blood vessel damage in
the retina. The severity of the disease is classified into four stages:
mild, moderate, and severe nonproliferative retinopathy, with the
fourth stage as proliferative retinopathy. Each of the first three
stages, labeled as ‘‘nonproliferative,’’ involves increasing damage in
the retinal blood vessels, ranging from (1) microaneurysms, (2) some
blocked blood vessels, and (3) cotton-wool spots (damage to retinal
nerves) to (4) several blocked retina blood vessels. The resulting lack
of oxygenation of the retinal tissue alerts the body to grow new blood
vessels for nourishment. The new blood vessels represent the most
advanced fourth stage, labeled ‘‘proliferative.’’ It begins with the
growth of new but abnormal and fragile blood vessels along the
retina and the clear vitreous gel that fills the eye. The rupture of these
thin fragile vessel walls can result in bleeding, which can lead to
severe vision loss or blindness. These new abnormal blood vessels can
also cause traction on the retina resulting in retinal detachment.
Symptoms can range from none to dark areas in the vision to specks
of dark or ‘‘floaters.’’ In 50% of persons with proliferative DR (PDR),
fluid can leak into the center of the retina, or macula where visual
acuity is greatest, and result in central retina swelling leading to
blurred vision. This condition is called diabetic macular edema.104
DR is the leading cause of adult blindness in the United States and
the most common diabetic eye disease. It can cause vision loss in
three ways: (1) rupture of blood vessels that occur in proliferative
retinopathy, causing intra-eye bleeding, (2) retinal detachment,
which occurs in proliferative retinopathy, or (3) fluid leaking into the
center of the macula, which occurs in about 50% of proliferative
retinopathy. At the end stage of the disease, new blood vessels can
form in other parts of the eye, leading to advanced glaucoma. In-
dividuals with type 1 and type 2 diabetes are advised to have an
annual comprehensive dilated pupil (mydriatic) eye examination,
which also includes visual acuity and tonometry (pressure) tests. The
ophthalmologist is able to detect blood vessel changes or leaking,
retinal swelling, pale or fatty deposits on the retina, and nerve tissue
damage. Macular edema treatment may require a photograph of the
retina or dye-based fluorescein angiogram to identify leaking vessels
and aid in creating a treatment plan. Glycemic control is associated
with the progression, if not prevention, of retinopathy.105 Main-
taining good blood pressure control is also important, as is control-
ling lipid levels and kidney disease (if present). Treatment for DR in
stage 4, or PDR, involves the use of a scatter laser procedure around
the retina away from the macula to shrink blood vessels.104
More recently, medications injected into the eye that selectively
target the stimulus of new blood vessels (anti–vascular endothelial
growth factor medications or control inflammation steroids) have
been used to impede proliferative disease or macular edema.106 Side
effects can include some loss of peripheral, color, or night vision. In
some cases, a surgical procedure (vitrectomy) may be required to
remove the blood accumulation within the eye or to repair retinal
detachments and release traction from the retina. Diabetic macular
edema is also treated with lasers, but a limited amount of burns
(typically less than 200) is performed near the macula to slow fluid
leakage and resulting in 50% less vision loss.104
DR Epidemiology
The major risk factors for DR include prolonged diabetes, un-
controlled hyperglycemia, high blood pressure, and LDL cholesterol,
as well as genetic factors. In addition to genetic factors, duration and
level of diabetes tend to increase the incidence of DR. The prevalence
of DR is higher in type 1 compared with type 2 diabetes. ‘‘Sight-
threatening retinopathy is 2.5 times more common in type 1.’’107
However, the prevalence and incidence of DR in type 1 diabetes have
been declining in industrialized countries, probably ‘‘the result of
improved glycemic control and possibly greater access to health
care.’’107 Still, DR is the leading cause of new cases of blindness in the
United States, and it may soon become the leading cause globally.107
The percentages of those with diabetes who are legally blind are 3.6%
of those with type 1 and 1.6% of those with type 2. The META-EYE
study found varying rates of DR among African Americans (49.6%)
and Asians (19%), as well as PDR variation of whites (12%) and South
Asians (1.29%).107
As in diabetes generally, regular screening and early diagnosis and
treatment of DR can be instrumental in saving vision, improving
quality of life, and perhaps savingmoney by diminishing the need for
costly treatment to restore vision.
Telemonitoring/Telescreening for DR
Annual examination monitoring for DR and other eye diseases is
recommended for all patients with type 1 and type 2 diabetes.108
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These examinations are typically performed by ophthalmologists in
their clinics. The reasons for DR telemonitoring/telescreening (tel-
eDR) are the same as those for other forms of telediabetes—namely,
early detection, prompt treatment, and prevention of exacerbations.
The teleDR tools enable patients to have these services in their home
communities or closer to where they live and work, thereby avoiding
unnecessary trips to the ophthalmologists. They also free ophthal-
mologists to see patients who need treatment and avoid long waiting
times for appointments. TeleDR involves the use of cameras to
photograph the retina, often by lesser trained professionals or tech-
nicians, but with reliable results.
Although there are several fundus imaging options (computed
tomography, magnetic resonance imaging, ultrasound, infrared
thermography, hyperspectral imaging, color Doppler imaging, pho-
to-acoustic ophthalmoscopy, blood flow magnetic resonance imag-
ing, fundus photography, fluorescein angiography, slit lamp), digital
photography offers the advantages of low-cost and ready access to
images, duplication, transmission, and archiving. Photography is the
primary tool in teleDR.107 There are two types of fundus images:
mydriatic (with pupil dilation) and nonmydriatic (without dilation).
Most programs use nonmydriatic photography so that patients’ eyes
would not have to be dilated for the examination. ‘‘Cameras that can
capture images through small, non-mydriatic pupils are tailored for
physiological dilation that occurs in a darkened room.’’109 This makes
them suitable for remote monitoring/screening programs, whereas
mydriatic cameras typically provide better fundus images. A non-
dilated pupil is smaller and allows less light into the eye chamber,
thereby limiting the field angle and the working distance from the eye
surface and increasing exposure to artifacts. In addition, there are
several variables to be considered, including the number of field im-
ages, image field angle, observational and photographic light sources,
working distance from the eye, regular pupil size, frame resolution,
filters used, and whether stereoscopic images were captured.
A 2012 comparison of the advantages versus disadvantages of
nonmydriatic fundus cameras is provided by Meszaros,110 making a
case for why nonmydriatic cameras will not replace dilated fundus
examinations. Nonmydriatic camera advantages include modest
cost, a variety of filters for image enhancement, quick, easy to use,
wide angle of the retina, little training required, and well tolerated
by patients. However, disadvantages include artifacts from over-/
underexposure, inability to detect abnormalities outside the photo-
graphic field, poor quality secondary to media opacity, and no ste-
reoscopic capability. The lack of stereoscopic capability has been
obviated by recent advances in technology, and nonmydriatic pho-
tography avoids the risk of dilation causing acute glaucoma and the
20-min wait time for dilation.
Themost important goal of teleDR is to differentiate patients with
no DR (not needing additional screening) from those with some
degree of DR requiring referral and a more advanced level of
monitoring and care. To determine the level of telescreening ca-
pability of a program, validation categories (1–4) were developed
by the American Telemedicine Association111 as shown in Table 6.
Screening levels are described in terms of Early Treatment Diabetic
Retinopathy Study and International Classification Levels of DR.
Category 1 includes those with an absence or very mild non-PDR
(NPDR) from those requiring additional screening to differentiate
the level and severity of DR. The highest category (4) is a screening
system that equals or exceeds any clinical or research DR screening
capability.
The most important limitation of teleDR is missing other ocular
diseases that may require the attention of an ophthalmologist. Si-
milar to research on telediabetes in type 1 and type 2 and GDM
screening, the research findings on teleDR are organized into three
sets—namely, (1) feasibility and effectiveness, (2) intermediate out-
comes, including patient adherence to testing, resource use, outreach,
and time to care, and (3) health outcomes.
Table 6. Tele-ophthalmology Programs and Systems
TELE-OPHTHALMOLOGY PROGRAM VALIDATION CATEGORY LEVELS
INTERNATIONAL
CLASSIFICATION
LEVEL OF DR ETDRS LEVEL OF DR
CATEGORY 1
SYSTEMS
IDENTIFY
CATEGORY 2
SYSTEMS
IDENTIFY
CATEGORY 3
SYSTEMS
IDENTIFY
CATEGORY 4
SYSTEMS
IDENTIFY
No apparent DR DR absent No or minimal DR Patients without
sight-threatening
DR or DME
No DR, NPDR, early and
high-risk DR, and DME
for follow-up and
treatment strategies
All levels of DR or DME;
photographs match, exceed,
or can replace ETDRS
photographs in any clinical
or research program.
Mild DR Very mild NPDR
Moderate NPDR Moderate NPDR More than minimal
DR—but patients
require additional
screening
Severe NPDR Severe NPDR, very
severe NPDR
Patients with
sight-threatening
DR, NPDR, and PDR
PDR PDR, High Risk PDR,
Very Severe or
Advanced PDR
DME, diabetic macular edema; DR, diabetic retinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study (30, stereo seven-standard field, color, 35-mm slides as
reference); NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
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The most important function of teleDR is the early detection of
abnormalities or pathology. Hence, as a screening tool, the two most
important measures of its success are ‘‘sensitivity’’ and ‘‘specificity.’’
These are normally presented as percentages. Sensitivity, or the true-
positive rate, is the percentage of people with pathology who are
correctly identified as such. It is also complementary to the false-
negative rate. Specificity, or the true-negative rate, is the percentage
of people without pathology who are identified as such. It is also
complementary to the false-positive rate. Typically, there is a trade-
off between the two measures. In instances where discovery of pa-
thology is critical, a high sensitivity rate is desirable to ensure that all
cases of pathology are promptly identified and treated. The trade-off
can be represented graphically as a ‘‘receiver operating characteris-
tic’’ curve.
Finally, it may be noted that the evidence in several studies did not
fit into a single category. In those instances, the study is reported only
once and typically under the most significant category.
Feasibility of TeleDR
A retrospective chart review of a very large mobile telescreening
program was conducted in several rural villages in India between
April 2009 and September 2010.112 The team consisted of trained
social workers (for organizing the program and registering the pa-
tients) and optometrists (for comprehensive clinical examination),
sometimes augmented by an information technology team (for
electronic medical registration). The initial examinations used non-
mydriatic fundus cameras. Abnormal findings were referred to oph-
thalmologists for further evaluation. In total, 54,751 patients
received eye examinations/screening. Of these, 58% had some form
of visual impairment: 59% uncorrected refractive error, 30.3% cat-
aract, and 3.3% DR with visual impairment. The authors concluded
that their mass screening model proved to be ‘‘efficient in delivering
comprehensive eye care to the rural population of India.’’112
A retrospective chart review of 643 patients over a period of nearly
7 years was conducted to describe the experience of using teleDR
among patients with diabetes and hypertension at a community
health center in rural West Virginia (published in 2012).113 Screening
was performed by a trained registered nurse using a nonmydriatic
retinal camera. About 5% required pupil dilation to obtain adequate
imaging. Ophthalmologists interpreted the images and followed up,
when indicated. The program detected unknown eye pathology in
44.5% of the patients. Thirty-three percent of the patients were re-
commended for prompt follow-up. According to the authors, this
experience ‘‘demonstrates the actual benefits of telemedicine in the
effective screening of diabetic and hypertensive patients for eye
pathology.’’113
DR Screening Intermediate Outcomes:
Screening, Adherence, Resource Use, and Cost
Obviously, teleDR by itself is an investigational tool. Hence, the
primary criteria for judging its quality would be sensitivity and
specificity. Nonetheless, some studies tried to ascertain whether
screening can also have spillover effects on diabetes-related health
outcomes, such as glycemic control, improvement in LDL, and arte-
rial hypertension. We decided to include both types of studies here,
presented in historical order.
We identified 23 such studies.114–136 Of these, nine were conducted
in the United States, five in France, three in Canada, two in Spain, and
one each in Mexico and Peru. The vast majority of the studies used
retrospective record reviews, and the samples varied from 158 to
38,595. These are summarized in Table 7.
We start with an initial set of six studies conducted between
2006 and 2008 (four in the United States and one each in France
and Canada).
The first, an RCT (n = 448), was conducted in the United States in
2006.114 All patients had diabetes and received their care from the
VHA. Patients in the intervention group received nonmydriatic
(without pupil dilation) digital retinal imaging with remote inter-
pretation in an ambulatory care setting, whereas patients in the
control group received their care from primary care providers in
regularly scheduled appointments. Patient adherence was measured
by documented evidence of a dilated eye examination in the ensuing
12 months from the start of the study. Twelve months after ran-
domization, patients in the teleDR intervention (n = 223) were more
adherent than those did not have the imaging (87% versus 77%).
Nearly two-thirds, or 64%, of the images were gradable. The re-
mainder had cataract, other diseases, or a small pupil. Teleretinal
imaging tended to ‘‘over identify the presence of DR.’’114 In other
words, they had a higher false-positive rate compared with those who
had their eye examinations in-person at the clinic. However, nearly
two-thirds of these false-positive, or 63%, for DR suggested other
ocular pathologies. The study concluded that ‘‘non-mydriatic tele-
retinal imaging in the ambulatory care setting may improve
screening rates for DR.’’114
Also in 2006, a retrospective review of 243 patients (482 eyes) was
conducted to determine sensitivity and specificity of nonmydriatic
stereoscopic retinal imaging in detecting DR among diabetic patients.
The project was conducted at four locations in the metropolitan
Washington, DC area.115 The system failed to transmit 4 out of 482
images, and 35% of the images were not gradable. Retinal thickness
could not be assessed in 21% of images. However, when the images
were gradable, ‘‘the overall sensitivity was 98%, and the specificity
was 100% for retinopathy within one grade of dilated funduscopic
examination.’’115
A retrospective analysis of a large dataset of electronic medical
records (n = 13,752) was conducted at the Joslin Diabetes Center over
a period of 2 years (2004 and 2005). The results were published in
2007.116 The patients were classified into four sets: ‘‘no eye care, eye
care outside the clinic, standard eye care at the clinic, and partici-
pants in the Joslin Vision Network telemedicine program.’’116 The
overall prevalence rate of DR was 23.1%, with a vast majority of
NPDR (77% of cases). DR frequency peaked at the sixth and seventh
decades of age and also increased with duration of diabetes. The
results indicated significant benefits accrued from participation in
the telescreening eye care program, especially improvement in both
A1c and LDL. The authors concluded that ‘‘such programs can address
BASHSHUR ET AL.
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the many aspects of care necessary to reduce risk of vision loss due to
diabetic retinopathy and other diabetes-related health outcomes.’’116
Based on their experience, they recommend the adoption of ‘‘a na-
tional screening DR program..’’116
Another retrospective study (n = 495) was conducted between
2003 and 2004, and also published in 2007.117 The subjects were 18
years of age or older who had diabetes and were using a nurse-
managed primary care clinic in the inner city. Nearly 90% were on
Medicaid. The participants were offered a choice between a tele-
medicine-based mydriatic digital retinal imaging system or referral
to an ophthalmology clinic at the next available appointment date
(typically within 12 weeks). In total, 201 patients chose digital
screening during their primary care visit, whereas 294 chose referral
to the ophthalmology clinic. All patients in the telemedicine group
were screened during the year, whereas only 31.3% of those selecting
the deferred appointment actually followed up with an in-person
examination. Inter-rater reliability was assessed in a subsample of 25
records, and it revealed a failure rate of 0.5% of digital image
screening. The authors concluded that digital image screening of
diabetic patients is ‘‘an efficient strategy to overcome traditional
barriers to diabetic eye care.’’117
A large-scale (n = 15,307) investigation of the effectiveness of
nonmydriatic fundus photography for detecting DR and adherence to
annual evaluation was conducted in a regional network in France in
2008.118 The project was labeled OPHDIAT (Ophthalmologie-Diabete-
Telemedicine). Fundus photographs were taken by trained orthoptists
(health professionals who evaluate and manage eye movement ab-
normalities) or nurses in 16 screening centers (located in general
practices, hospitals, prisons, and primary care centers) in the Iˆle-de-
France region. All locations were linked to a telemedicine center
where ophthalmologists graded the images. Each screening lasted
about 15min. Patients with a previously diagnosed DRwere excluded
from the analysis. After 28 months, in total, 15,307 screening ex-
aminations were completed. Diabetic retinopathy was detected in
23.4% of the cases, and 9.7% of the images in at least one eye could
not be graded, mostly because of lens opacity or small pupil. After the
screening, 25.2% were referred to an ophthalmologist for DR, cata-
ract, or nongradable images. The results of the study confirmed the
importance of annual DR screening for people with diabetes, espe-
cially in view of the fact that DR incidence has been increasing (es-
timated at the rate of 4.8% in 5 years, and projected to increase by
50% by 2025.
A Canadian descriptive study (n = 3,505), conducted from July
2003 to December 2005, was based on screening patients with dia-
betes in 182 pharmacies located in urban communities in five
provinces: Quebec, British Columbia, Alberta, Saskatchewan, and
Manitoba.119 The results were published in 2008. A photographer
used mobile phones to capture the images with the assistance of a
nurse, who performed mild dilation when necessary for quality
photographs. High-resolution (1280 · 980 pixels) images were for-
warded to ophthalmologists for interpretation and timely referral, as
indicated. The service was offered free of charge. For 38% of the
patients, this was their first eye examination, and an additional 30%
had not received an eye examination in over 2 years. The results of
the screening revealed a 22.5% prevalence rate of DR pathology,
2.4% requiring urgent referral for various reasons, and 10.1% re-
quiring nonurgent referrals. A poor-quality image was observed in
only 0.7% of the entire group. The cost estimate for the telescreening
examwas around $100, similar to the cost of conventional screening.
The authors highlighted the benefits of telescreening in terms of
lowering barriers to screening for a diabetic population in need of
such services, while ‘‘maximizing the use of limited ophthalmologic
resources.’’119
A retrospective analysis of data from a large DR screening program
in a rural county in Finland was conducted on 17,471 patients (with
type 1 or type 2 diabetes) from 1999 to 2006. The report was pub-
lished in 2009. The purpose of the study was to ascertain the effects of
the program on outreach, coverage, and referral.120 Screening was
performed initially by trained nurses using a mobile digital non-
mydriatic fundus camera. Ophthalmologists did the final scoring of
the images. Images showing clear abnormalities were referred to the
eye clinic for follow-up. Prior to this program, only type 1 diabetic
patients were screened at the regional hospital. This program enabled
screening for 85% of all patients with diabetes in the region. Tele-
screening was especially effective in diagnosing nonproliferative
retinopathy, which enabled early treatment. It was also effective in
having fewer cases referred for follow-up, thereby decreasing the
workload of ophthalmologists at the regional hospital. A survey of
patients revealed high satisfaction levels with the screening.
Another large observational study (n = 1,147; 90% with diabetes
type 2) evaluated the feasibility of DR telescreening, as well as its
effectiveness in estimating DR prevalence and in outreach. It was
conducted in France in 2009.121 The patients were screened con-
secutively upon recruitment over a period of 18 months, using a
nonmydriatic fundus camera with three 45 digital images per eye.
The images were subsequently transmitted to an ophthalmology
department in a referral hospital for grading. Of the total study
population, 45% never had a fundus examination before this project.
About 30% of them required referral to an ophthalmologist or had
unreadable photographs. Findings from this study demonstrated the
usefulness of telescreening for DR in terms of identifying patients
requiring complete eye examinations.
Three separate articles were published from a regional network of
telescreening centers in the Iˆle-de-France in France, OPHDIAT. The
network was established in 2004 and continues to be operational. Its
primary objective is to provide comprehensive telescreening fundus
examinations for diabetic patients on an annual basis. The centers are
linked to a central server, the OPHDIAT Reading Centre, at reference
hospitals. Each screening center is staffed by trained nurses and or-
thoptists and equipped with a digital, nonmydriatic camera. All im-
ages are read and graded by ophthalmologists.
The first report, published in 2009,122 was based on a retrospective
study of 500 case reports before and after the implementation of
OPHDIAT in five reference hospitals. At each hospital, 100 case re-
ports (50 before and 50 after selected at random) were assessed to
determine the average proportion of people screened per site (as an
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indication of successful outreach), the duration of fundus examina-
tions, and their effectiveness in terms of human resource use. The
results demonstrated an improvement in DR screening outreach
(50.4% before and 72.4% after), whereas the prevalence of DR was
11.1% before and 12.7% after (although the difference is not statis-
tically significant), and a shorter time for the ophthalmologist to
make a diagnosis (0.9 half-day before and 0.32 half-day after),
suggesting greater efficiency in telescreening compared with in-
person examination.
Two other articles were published in 2012 from the OPHDIAT
program. The first was a report on clinical and biological risk factors
associated with DR.123 It was based on an analysis of 254 patients
who were studied in detail in order to determine the staging or
progression of DR. At the initial screening, 236 showed no signs of
DR, whereas 18 patients did. Excluding the 18 patients having
preexisting DR, the 3-year DR follow-up focused on the remaining
236 who were free of DR at baseline. Of this latter group, 33 de-
veloped DR (29 with mild NPDR and 4 with moderate NPDR). None
of these had proliferative DR at the end of 3 years. The general
conclusion from this study suggests that diabetes can be controlled
and that telescreening for DR is effective in identifying early stages
of DR.
The second publication in 2012 described the results of the 5-year
experience of this program.124 Between June 2004 and December
2009, in total, 38,596 patients with diabetes were screened at 17
hospitals, 11 primary healthcare centers, and 2 prisons. Around 73%
had either mild or no DR, 26.6% were referred to an ophthalmologist,
and 9.9% had nongradable photographs. This failure rate declined
over the 5 years (from 10% to 8.2%). Nearly 94% of the photographs
were interpreted on the day they were taken. Overall, the total
prevalence of DR in this region was 24.3%. Based on the 5-year
experience, the authors concluded that DR telescreening (they re-
ferred to it as tele-ophthalmology) is a reliable DR screening tool, is
well accepted by patients and by ophthalmologists, saves time by not
needing to dilate patients’ eyes, is convenient because it can be done
outside of office visits, and is an effective tool to offset the increase in
the population with diabetes and the limited availability of oph-
thalmologists to serve them.
A retrospective analysis of consecutive cases (n = 394) of DR tel-
escreening from 2005 to 2007 in rural Alberta was published in
2010.125 Images were captured by mydriatic, seven-field digital
retinal photography and three-dimensional software. These were
subsequently transferred to Edmonton for evaluation. Results indi-
cated a 24.9% prevalence rate of NPDR and 2.3% with PDR. Because
the screening program was conducted in rural areas, it was credited
with saving the patients 450 trips, 1,900 h of travel time, and
180,000 km over a 3-year period. However, a large majority of pa-
tients (76.8%) did not follow up or attend referred appointments in a
timely manner. Eventually, 87.3% did so.
Another retrospective study (n = 1,223) evaluated the effectiveness
of telescreening for DR in a primary care setting in Spain over a 12-
month period (published in 2010).126 The providers were general
practitioners specially trained to evaluate nonmydriatic images for
grading DR using the International Classification for Diabetic Re-
tinopathy. The results were assessed for specificity and sensitivity.
Overall, 24% were found to have DR, and 2% of the images were
unreadable. Subsequent evaluation by ophthalmologists on a subset
sample determined that ‘‘the sensitivity [true positive rate] of GPs
[general practitioners] for detecting diabetic retinopathy was 90.9%;
the sensitivity for detecting treatable lesions was 99.2%.’’126
An observational study (n = 676) conducted in Mexico in 2011 was
aimed at measuring coverage of DR screening in primary care set-
tings and agreement between ophthalmologists and family physi-
cians.127 Mydriatic photography was conducted among diabetic
patients in three urban primary care health centers. The study re-
vealed substantial variations in coverage of DR screening between
the clinics. However, the rate of pathological findings detected from
retinal photographs by family physicians was 27%, but only 9% by
ophthalmologists. These rates improved in year 2. There was an
overall sensitivity of 97% and specificity of 80%.
A prospective analysis of data from a large screening program
from 2007 to 2010 (n = 1,311) was conducted in Peru.128 The results
were published in 2011. Screening was conducted by a nurse using
a nonmydriatic fundus camera. Patients were placed in a dark room
to allow natural pupil dilation. The purpose of the study was to
estimate the prevalence rate of DR among patients with type 2
diabetes. More than one-half, or 58.3%, of the participants never
had an ophthalmological evaluation before. To ensure image
quality, the Vanderbilt Ophthalmic Imaging Center reviewed im-
ages and grading and observed an 86% concurrence (or matching)
rate between centers during the first year. DR was detected in
23.1% of patients (20.3% NPDR and 2.8% PDR). Prevalence rates
increased with duration of diabetes, arterial hypertension, neu-
ropathy, or renal complication. Also, DR impairment peaked in the
51–70-year age group. However, DR prevalence did not vary by
gender. In those with DR, blindness was twice as common and low
vision was more prevalent, compared with their counterparts. The
analysis demonstrated that retinal telescreening was feasible and
efficient, allowing specialists to intervene promptly among those
with the most severe diseases requiring vitrectomy surgery and
laser photocoagulation.
A retrospective cohort study (n = 980) tracked the predictors and
progression of DR among Alberta First Nations communities over a
10-year period, from 1999 to 2009.129 Results were published in
2012. Eligibility for inclusion in the study was based on the avail-
ability of gradable retinal photographs, two or more photographic
records, and an initial screening. Study subjects received a minimum
of two screenings during the study period, which included serial
laboratory testing and stereoscopic mydriatic photography of the
retina. At baseline 20.7% had DR: 18.3% NPDR and 2.5% PDR. A
small minority of the study population experienced progression of
DR over time, which occurred at a median of 7.6 years, and it was
associated with poor glycemic control and hypertension. Ironically,
these two factors are controllable. The authors concluded that ‘‘tar-
geted individualized care to reduce blood pressure and control blood
sugars could reduce the progression of diabetic retinopathy..’’129
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The effectiveness of telescreening in identifying and referring
undetected vision-disease in a homeless population was investigated
in a U.S. descriptive study (n = 341) in 2012.130 The study collected
screening data on visual acuity, blood pressure, pulse/oxygen satu-
ration, BMI, and intraocular pressure among participants at soup
kitchens and community shelters. Apparently, the researchers did not
use a probability sampling scheme for representing the target pop-
ulation. Hence, there is no way of telling the extent to which this
sample represents the larger population of homeless people. At any
rate, this at-risk population, with limited access to standard oph-
thalmic care, was screened using a nonmydriatic retinal camera for
image capture and transfer to an offsite clinic for evaluation. Ocular
disease was detected in 105 patients (or 30.8%), including glaucoma
(n = 34), cataracts (n = 22), DR (n = 5), optic atrophy (n = 1), age-re-
lated macular degeneration (n = 1), and other retinal disease (n = 43)
with visual impairment (10%). These estimates were about 2.5 times
higher for this population than the national average in other studies.
Poor image quality was encountered in 13 examinations because of
small pupil size and ocular opacity, which prevented a diagnosis and
required patient referral for a regular office examination. The aver-
age screening cost was about $37.50 per patient, which demonstrated
a priori the cost-effectiveness of this modality of screening for those
with limited medical access and no financial resources.
A descriptive cross-sectional study (n = 2,435 patients with dia-
betes: 2,376 with type 1 and 59with type 2) was conducted from 2006
to 2009 in Spain and published in 2012.131 This study evaluated the
benefits of telescreening in terms of early diagnosis, treatment, and
communication between primary care providers and ophthalmolo-
gists. A trained nurse used a nonmydriatic camera to take three 45
retinal photographs, and two ophthalmologists evaluated the images
at a viewing station at the reference hospital. An overall DR preva-
lence rate of 17.9% was observed, of whom 80.7% had mild to
moderate NPDR, 12.2% had severe NPDR, and 2.3% had PDR. In
addition, there was a general incidence of diabetic maculopathy of
4.8% across all levels of DR over the study period. Most of the
screenings were performed without dilation, except for 127 patients
who required a drop of tropicamide in order to obtain acceptable
images from 86 patients. The remaining 41 with unacceptable image
quality were referred to a specialty center. The two primary benefits
realized from telescreening were (1) avoidance of more expensive
conventional screening and (2) the timely detection, diagnosis, and
treatment for DR. The turnaround time was 15 days from photogra-
phy to treatment, whereas conventional assessments using (mydri-
asis, slit lamp, and 78 D lens) had a 3-month waiting list, followed by
2–3 months of additional waiting for treatment.
A prospective evaluation (n = 158) of retinal imaging by trained
certified retinal imagers was conducted in the Joslin Vision Network
in 2012.132 It was aimed at evaluating the ability of certified retinal
imagers to detect and grade DR. Their grading was compared with
that of optometrists. Sight-threatening DR (stDR) images of 316 eyes
were taken and immediately graded by imagers, resulting in 48 (15%)
images being classified as stDR. ‘‘The sensitivity and specificity of
identifying stDR at the time of imaging by a certified imager is 1.00
[100%] and 0.97 [97%] respectively.’’132 There was 100% agreement
between imagers and reads regarding ungradable images, which
accounted for 12% of all cases. Imagers identified 48 images with
stDR, whereas optometrist readers reclassified 6 as mild NPDR,
yielding 88% accuracy in identifying stDR. Of note in this study is
that imagers had BA degrees, had no previous medical experience,
and had received an intensive 3-day training program involving
camera and software usage, diabetes, ocular anatomy, DR, review of
(non-)diseased eyes, and common eye disorders. The primary con-
clusion here is that lower-cost imagers can perform well and thus
free ophthalmologists for more complex interventions within their
domain.
A retrospective analysis of a large electronic database (n = 14,866)
from the Finnish Register of Visual Impairment was conducted in
2013 and published in 2014.133 It compared mobile eye screening
with traditional models. In Finland, all patients with diabetes are
offered free access to DR screening via fundus photography. Imaging
technicians record the images using a fundus mydriatic camera and
transfer them to a central server, where nurses prescreen the images.
When DR or other abnormalities are detected, the images are for-
warded to an ophthalmologist for follow-up. Results from 5 years of
telescreening of patients with either type 1 or type 2 diabetes revealed
that patients with DR were being screened annually and that patients
who needed further treatment were also referred to the reference
hospital. Evaluations resulted in no DR detected (43%), mild DR
(23%), moderate or severe DR (31%), and PDR (3%). Those requiring
treatment for PDR or macular edema decreased from 5% in 2007 to
3% in 2011. Nurse-read examinations increased from 46% in 2007 up
to 74% in 2011, freeing ophthalmologists for more complex inter-
ventions and reducing screening costs. Greater nurse readings still
yielded 95–100% accuracy, when compared with those of ophthal-
mologists. Time delays from photography to hospital treatment de-
creased from an average of 127 days for conventional screening
down to 75 days for telescreening. Overall DR impairment decreased
86% (1.8 to 0.25/100,000 patients) with the intervention versus only
35% (2.3 to 1.5/100,000 patients) with conventional screening. This
analysis demonstrated faster treatment, higher-quality images, re-
duced DR impairment, and use of non-MD clinicians for screening.
DR Screening: Cost
Three studies investigated the economic effects of DR screening in
terms of cost savings, all U.S.-based and published in 2012–2013.
A cost savings analysis of DR telescreening was conducted on a
program in a small, remote, rural, mountainous, and economically
depressed community in West Virginia from 2003 to 2009.134 The
results were published in 2012. Of the 937 residents using the Tug
Regional Medical Center for routine visits, 659 were in need of
ophthalmic screening. Fundus photographs were taken by a nurse
during routine clinical visits using a nonmydriatic camera and the
images were forwarded to an offsite ophthalmologist for interpre-
tation. Of the 659 images, 288 (or 43.7%) readings were abnormal,
but only 195 required follow-up with an ophthalmologist located an
hour away. Cost savings estimates considered travel, missed work,
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and theMedicare payment for binocular screening. Total cost savings
over the 7-year period were calculated at $71,189.28 (after sub-
tracting $23,940.00 for the fundus camera and additional expenses),
resulting in an average cost savings of $153.43 per patient. Although
a cost savings was gained, many variables were not addressed, such
as false-positives and -negatives (specificity and sensitivity) and
patient compliance. Nonetheless, using a minimumwage of $7.25 for
residents in this community may yield a very different cost benefit in
settings where wages are higher.
The second was a cost analysis (n = 611) that compared a ‘‘tele-
medicine-based’’ retinal imaging evaluation with conventional
ophthalmic fundus examination of diabetic patients.135 All patients
were users of a Federally Qualified Community Health Center. A
nurse took the images using a nonmydriatic fundus camera and saved
them on a network server. An offsite ophthalmologist read the im-
ages. The costs for standard care were based on 2009 Medicaid re-
imbursement rates, whereas the cost of the telemedicine systems
included per patient cost for medical assistant, ophthalmologist,
capital cost (equipment and training), maintenance, and transpor-
tation. The cost of the traditional method of DR screening was $77.80
per patient, whereas the telescreening cost was $40.40.
The third was a cost-effectiveness analysis of telescreening for DR
in a VHA population based on a simulation model of the experience
of 900 patients with type 1 or type 2 diabetes.136 The model simulated
the progress of disease and testing decisions involved in ‘‘no
screening, teleretinal screening, or ophthalmologist screening,’’
whereas the treatment is a form of laser surgery. Based on this model,
‘‘telescreening was cost-effective under most conditions.’’136 It may
be noted that a much earlier (2000) cost-utility analysis suggested a
more tailored timing for screening intervals among patients with type
2 diabetes to fit individual circumstances would be warranted.137
Summary and Conclusions
Our review of the telemedicine intervention in all
manifestations of diabetes (telediabetes) revealed a closed
loop system of care composed of a number of stages, from
patient to provider and return, as shown in Figure 1. In
Stage 1, patients collect their own diabetes-related data
(including insulin dosage, glucose levels, body weight,
level of physical activity, etc.). They may use glucose
meters and short questionnaires. One variant of the entry
point to this telediabetes circuit involves nurse-initiated
telephone calls to assess, monitor, and motivate patients.
In Stage 2, patients transmit the data electronically to a
call center or clinic, staffed by trained nurses or a nurse-
lead team. In Stage 3, these data are stored, collated, and
processed by various algorithms, display time trends, and
trigger alarms when significant deviations in values are
exceeded. Patients are alerted to these situations and
given explicit guidance and assistance. Nurses may
communicate with physicians, as indicated by the data,
who will provide medical assistance or directions to re-
ceive in-person care. In addition, nurses may provide
individualized education/motivational information directed toward
encouraging patients to adopt healthy life styles. In DR, the focus is
on screening underserved patient populations in their respective
communities and periodic monitoring of patients with diabetes after
their initial visit with an ophthalmologist for early detection of
complications and prompt treatment. In brief, the core functions in
telediabetes, teleGDM, and teleDR include the collection, storage,
analysis, and retrieval of clinically relevant information and the at-
tendant actions pursuant to the findings from these data.
Our analysis of the scientific evidence aimed at identifying and
explaining the merit of telediabetes was predicated on two coter-
minous assumptions—namely, (1) credibility of empirical findings
derives from the application of sound and robust research designs
and methodologies and (2) the relevance of these findings for policy
development and clinical decision-making derives from their speci-
ficity in terms of the various parameters of the applications that were
assessed as well as their context. Hence, we selected for our review
and analysis only robust/rigorous studies, defined operationally as
RCTs or other research designs approximating an RCT and sample
sizes of 150 or more cases. Few exceptions were warranted vis-a`-vis
sample size when the research was deemed particularly significant or
innovative. On the other hand, surveys and retrospective record re-
views are the methodologies of choice for estimating population-
based values such as prevalence and incidence rates. Finally, because
of the rapid obsolescence of the underlying technology, we limited
our time purview to materials published from January 2005 to De-
cember 2013.
Working within publication constraints, we excerpted and in-
cluded information on the contexts, target populations, methodolo-
gies, and intervention details for each study sufficient to explicate the
logical and empirical links between specific inputs and outputs. This
approach was deemed appropriate because of our observation that
Fig. 1. The telediabetes closed loop system. A1c, glycated hemoglobin A1c.
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the effects of the telemedicine intervention in chronic disease man-
agement, and perhaps more generally, cannot be fully understood
from overarching reviews or even meta-analyses that are based on
categorical conceptions of telemedicine (e.g., stated simply as tele-
medicine versus in-person care) or collective nuanced conclusions.
The search for policy-relevant evidence in telemedicine research
should not be aimed at making blanket conclusions on the merits, or
lack thereof, resulting from inputting multiple studies of various
types into a ‘‘statistical black box’’ from which conclusions emerge.
Indeed, the literature should not be organized to draw conclusions
simply as a voting scheme or statistical process to produce categor-
ical or nuanced findings or outputs in one of three columns—positive,
negative, or neutral—in response to a single hypothesis.
As with studies of the telemedicine interventions in other chronic
diseases, there were variations in the definition of telediabetes from
study to study in terms of setting, technology, staffing, duration,
frequency, and target population. The empirical studies investigated
the effects of various configurations of these variables on various
combinations of outcome measures. In addition to feasibility, mea-
sures of effects included intermediate outcomes (use of service,
compliance) and health outcomes (glycemic and lipid controls,
weight, diet and exercise). We used the latter variables as surrogate
outcome measures because of their correlation with diabetes control
and functional performance.
Neither the telediabetes intervention nor its outcomes should be
viewed as unidimensional in nature. Hence, the most meaningful
way to interpret the empirical evidence from this research is to
consider the findings from each study in the context of a complex
matrix of inputs and outputs. Viewed this way, the results from
specific studies provide partial answers to our understanding of
the complex sets of relationship between inputs and outputs in
telemedicine research. This is not a puzzle in a classical sense.
Instead, it constitutes an emerging pattern of cause-and-effect
relationships in a multidimensional space. From policy and pro-
grammatic perspectives, this approach would enable us to identify
optimal configurations of technology, human resources, and other
structural attributes of telemedicine as they pertain to costs and
benefits.
In terms of technology, the telephone was the predominant tool for
connectivity in studies of telediabetes, whereas the Internet was the
prevailing mode in connectivity for teleretinopathy. Telephone
connectivity entailed various types and levels of sophistication, in-
cluding interactive voice recognition and automated capture and
transmission of data, as well as smartphones and applications on
mobile phones. Some studies used a combination of telephones and
Internet for connectivity. Data-gathering technology is a critical
component in telemonitoring/telescreening patients with diabetes or
its retinopathy. The glucose meter is the usual tool for glucose
monitoring, as is nonmydriatic photography in retinopathy. In terms
of personnel, the vast majority of studies in telediabetes used nurse
practitioners, individually or in teams, as the lead providers who
received the data from the patients and also provided coaching and
educational materials. Few studies used dietitians and educators in
combination with nurses. Nurses also conducted teleDR photogra-
phy, as did orthoptists and trained photographers. The duration of the
study periods varied from 1 month to 5 years.
. The telephone was the method of choice for connectivity in
telediabetes, sometimes in combination with the Internet.
. The typical providers are nurses, sometimes in teams with other
specially trained personnel.
Initially, we organized the findings by diabetes type in the study
population (i.e., those with type 1 and/or type diabetes, GDM, and
DR). We did not differentiate the studies any further than this
classification, even though some studies selected patients on the
basis of severity, complications, age, and SES. Finally, we organized
the empirical findings on the basis of two sets: intermediate out-
comes and clinical outcomes. On the other hand, the merit of teleDR
is assessed primarily in terms of effectiveness as a screening/
monitoring tool. Hence its outcomes pertain mostly to sensitivity
and specificity.
The ultimate aims of telediabetes, teleGDM, and teleDR are (1)
glycemic control through various means, including glucose moni-
toring, compliance with prescribed medication regimen, and the
adoption of healthy life styles and (2) early detection of disorders and
prompt treatment. Changes in life style are critical for overweight/
obese individuals and for those who lead a sedentary life style. Be-
cause of their higher risk for DR and its associated complications, it is
also important for patients with diabetes to have periodic retinopathy
screening and monitoring for early detection of complications and
prompt treatment of problems.
We reported the results of four studies that focused on interme-
diate outcomes in telediabetes for type 1 and/or type 2 diabetes. The
empirical findings from these studies are remarkably consistent in
that all reported positive results, albeit based on only four studies.35–
38 The effects were measured in terms of reduction in use of service
(decrease of 44% in rehospitalization among VHA patients receiving
comprehensive case management).37 In addition, there was evidence
of increased adherence to periodic assessment35 and average annual
savings of $2,816 among patients using a Federally Qualified Health
Center.38
. Cost savings among users of a Federally Qualified Health Center
of $2,816
. Participation in telediabetes increased adherence to prescribed
testing.
In total, 16 studies that met the inclusion criteria for this analysis
investigated the effects of telediabetes on diabetes-related outcomes,
defined here as control over glycemic level, blood pressure, LDL, and
body weight. These studies were conducted in 10 countries (six in the
United States, two in France, and one each in Finland, Spain, Italy,
the United Kingdom, The Netherlands, India, Korea, and Taiwan).
Eight were based on RCT design, three case-control, and two record
review, and the remaining three were observational studies. Sample
size varied from 146 to 1,797. In addition, this set included 9 VHA
studies and 16 separate reports from the IDEATel project.
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With minor exceptions, conclusions from studies pertaining to the
effects of telediabetes on related clinical and behavioral measures are
remarkably consistent and positive. Outcomes were measured in
terms of glycemic control (A1c), blood pressure, body weight, and
LDL. It is interesting that a small percentage difference in A1c (for
example, a decrease from 6.5% to 5.6%) means an actual change in
diagnosis from diabetes to normal. An A1c level of 4.5–5.6% is
considered normal, whereas 5.7–6.4% is prediabetes, and ‡ 6.5% is
diagnosed as diabetes.
The data summarized in Table 2 reveal a near-universal trend of
A1c decline as a result of patient active participation in a nurse-led
regular telediabetes program based on telephonic contacts with pa-
tients to help them monitor their glucose levels, titrate their medi-
cation, and adhere to an appropriate diet and exercise regimen. There
were two exceptions. One study of the effects of a supplemental
telephonic disease management program among an underserved,
predominantly Hispanic and African American low-income (Med-
icaid) population reported no significant effects of telediabetes on
clinical or behavioral outcomes.42 Depression was highly prevalent
in both the intervention and control groups. A study from The
Netherlands (that also included patients with depression) focused on
Web-based cognitive therapy for only 1 month. As in the study
above, similar neutral findings regarding the effect on A1c were
reported.46 The findings from both studies are open to different in-
terpretations. Of course, the 1-month duration of the study in
The Netherlands is far too short to expect any reliable results. But,
the findings from the U.S. study may be explained differently. One
plausible explanation may relate to a hierarchy of need, that is, pa-
tients suffering from depression may be more in need of dealing with
their depression than their diabetes.
. With minor exceptions, telediabetes resulted in improved dia-
betes-related outcomes.
. Weight monitors are effective in weight control, especially
among the young.
. Patients with depression may have higher priorities and may
not participate actively in telemonitoring.
In addition to these studies, there were 9 VHA studies and 16
reports from the IDEATel project.
The findings from the VHA studies were positive in terms of A1c
and other clinical indicators. In addition, researchers reported several
other kinds of effects, including decline in mortality,64 improvement
in physical and social functioning,56 enhanced patient perceptions/
knowledge,63 and reduced use of service.57,58
. Participation in the VHA home monitoring program reduced
hospital re-admissions in the VHA by 44%.
. VHA studies reported improved adherence to glycemic testing,
improved physical and social functioning, a decline in mor-
tality, and reduced use of service.
The 5-year IDEATel project produced 16 articles encompassed
several substudies, both short term (1 year) and long term (3 and
5 years). Empirical findings from this project show consistent im-
provements in glucose levels, blood pressure, and LDL on the part of
the participants. These effects tended to increase with time (i.e., the
longer patients remained in the program, the more appreciable the
effects). In addition to clinical improvements, special topic analysis
of data from the project indicated improvements in psychosocial
outcomes,71 preference for automated and in-home learning by
participants,78 and improved task performance and slowing of
physical decline79 and cognitive decline,81 as well as reduced co-
morbidities.82 On the other hand, the intervention did not prove to be
cost-effective, which was explained by the authors as being the result
of customized expensive equipment.
. Participation in the IDEATel project among low-income and
minority Medicare beneficiaries resulted in a decline in diabe-
tes-related clinical measures.
. Expensive technology may reduce, if not eliminate, cost-ef-
fectiveness of telediabetes.
Only three GDM studies met the inclusion criteria. A ‘‘weight gain
tracker’’ linked to a Web site and mobile phones proved to be useful
but did not result in any definitive findings.99 However, another
study reported better glycemic control among women receiving a
glucose meter and reporting values every week. The same group
experienced a lower rate of cesarean section as well as fewer mac-
rosomic infants.100 The latter finding were also confirmed in another
study.101
. TeleGDM proved to be effective in glycemic control as well as
reduced cesarean section deliveries and macrosomic babies.
Interest in regular screening for DR via photography is both strong
and widespread. Its appeal derives from two sources: (1) The risk of
DR and potential vision loss increase with the duration and severity
of diabetes. Hence, early detection and prompt medical intervention
are critical to diminishing these risks. (2) The requisite photography is
relatively inexpensive and is easy to implement in community set-
tings, away from clinics and private offices. The evidence from
several very large screening programs confirms the reliability of
nonmydriatic photography as a tool for community screening of DR.
The percentage of gradable images varied from a low of 65% to a high
of 100%. Both false-positive and false-negative rates were low, and
the effectiveness of this mode of screening in outreach has been
universally confirmed. Additional benefits were accrued in terms of
expediting the referral to ophthalmologists when indicated.
. Nonmydriatic photography is easy to administer by trained
nurses, orthoptists, and photographers, is relatively inexpen-
sive, is fast, and is reliable.
. TeleDR improves outreach, early detection, and prompt treat-
ment of DR.
The evidence presented and conclusions pertaining to telediabetes
derive from a targeted selection of studies published over the last
decade. These studies met our criteria in terms of scientific rigor and
statistical power. The majority of these studies focused on type 1 and
type 2 diabetes and retinopathy. Considerably fewer studies focused
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on GDM. The studies included here were conducted in a wide variety
of settings based on a variety of interventions for a wide spectrum of
conditions and populations. Notable also is the global distribution of
pertinent telediabetes research, reflecting the global concern with
diabetes and its sequelae. The extensive variety of institutional and
geographic settings, populations, interventions, and the like, al-
though perhaps not providing the depth required by some readers to
draw more definitive conclusions regarding the benefits and costs of
telediabetes, as well as the breadth of the research dimensions, leads
us to conclude that telediabetes warrants a prominent place in the
medical armamentarium that must be marshaled to face and perhaps
change the future path of diabetes.
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